Neural stimulation control device and system including vibration device, and method for alleviating brain function decline using same

The neural stimulation control device using tVAS with a vibration device addresses accessibility and safety issues by inducing mechanical resonance in deep brain tissues, effectively alleviating cognitive decline and structural atrophy through stable energy transmission.

WO2026240539A1PCT designated stage Publication Date: 2026-11-19ARIBIO CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/KR2026/096581
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2026-03-16
Filing Date
2026-05-04
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

Existing non-invasive brain stimulation technologies for cognitive decline and neurodegenerative diseases face limitations in accessibility, safety, and efficacy due to high-intensity visual-auditory fatigue, stress, and potential safety risks, while conventional vibration devices fail to induce mechanical resonance in deep brain tissues effectively.

Method used

A neural stimulation control device and system using transcranial vibroacoustic stimulation (tVAS) with a vibration device that minimizes noise and energy loss, applies critical acceleration to directly stimulate mechanoreceptors, and induces mechanical resonance in deep brain tissues through the skull, featuring a modular structure with an integrated cone damper and bobbin, and a spring-acting rubber frame to ensure stable energy transmission.

Benefits of technology

The device effectively alleviates brain atrophy, inhibits cerebral blood flow reduction, and reorganizes brain networks, significantly delaying cognitive decline and structural atrophy progression, while ensuring safety and comfort for long-term use.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure KR2026096581_19112026_PF_FP_ABST
    Figure KR2026096581_19112026_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to a neural stimulation control device and system including a vibration device for improving the cognitive function of a subject having cognitive impairment or a neurodegenerative disease, and a method for alleviating brain function decline using same. The neural stimulation control device according to the present invention comprises a vibration device which is worn on the head of a subject having cognitive impairment or a neurodegenerative disease and applies transcranial vibroacoustic stimulation to improve cognitive function, wherein the vibration device applies, to the head of a subject, physical transcranial vibroacoustic stimulation having a frequency selected or adjusted for each subject, within a range of 20 Hz to 120 Hz, the stimulation being controlled to a critical acceleration at which vibration energy, which is a mechanical wave, is transmitted through the skull directly into brain tissue to directly impinge on and stimulate mechanoreceptors within brain tissue, and induce mechanical resonance deep within the brain.
Need to check novelty before this filing date? Find Prior Art

Description

Neurostimulation control device including a vibration device, system, and method for alleviating brain function decline using the same

[0001] The present invention relates to a neural stimulation control device and system including a vibration device, and a method for alleviating brain function decline using the same. More specifically, the invention relates to a medical vibration device, an integrated control system, and a neural stimulation method that can effectively alleviate symptoms related to cognitive function decline by applying Critical Acceleration-based transcranial Vibroacoustic Stimulation (tVAS) that is worn on the head of a subject with cognitive impairment or degenerative brain neurological disease to directly strike mechanoreceptors within brain tissue and induce mechanical resonance in the deep brain, thereby alleviating the progression of atrophy of total brain volume and deep brain structures (hippocampus, amygdala), defending against a tendency to reduce cerebral blood flow, and inducing brainwave network realignment.

[0002] With the aging of the population, the number of patients with neurodegenerative diseases, including Alzheimer's disease (AD), and cognitive impairments caused by them is continuously increasing.

[0003] Dementia is a disease characterized by a decline in learning and memory caused by various factors; among these, AD is known as the most common form of dementia and is a representative age-related degenerative brain disease.

[0004] Clinically, this AD is characterized by cognitive decline and behavioral and emotional changes, and neuropathologically, it has been reported to include the accumulation of amyloid-beta (Aβ) plaques, the accumulation of hyperphosphorylated tau protein, a decrease in synaptic density and neuronal loss, and a decrease in acetylcholine (ACh) neurotransmission due to the loss of cholinergic neurons in the basal forebrain.

[0005] Furthermore, as the disease progresses, it leads to pathological imbalances in the brainwave network, a decrease in cerebral blood flow metabolism, and ultimately, irreversible structural atrophy of deep brain structures, including the hippocampus and amygdala, as well as whole brain volume.

[0006] Currently, drugs such as donepezil, which increase ACh concentration in the synaptic cleft by inhibiting central acetylcholinesterase (AChE), are widely used to alleviate AD symptoms.

[0007] However, these AChE inhibitors are observed to cause gastrointestinal adverse reactions such as nausea, vomiting, and diarrhea relatively frequently, and cardiovascular adverse reactions such as bradycardia and syncope have also been reported, raising concerns about certain limitations in terms of tolerability and safety during long-term administration.

[0008] Furthermore, amyloid-targeted antibody therapies and the like carry a risk of serious side effects such as microhemorrhage or edema (ARIA). Consequently, there is a strong demand for the development of safe non-pharmacological treatments that can preserve macroscopic brain structures and improve cognitive function while mitigating the burden of drug side effects.

[0009] Against this backdrop, non-invasive brain stimulation (NIBS) technologies, such as transcranial direct current stimulation (tDCS) and transcranial magnetic stimulation (TMS), have been studied. However, existing techniques are operated as clinic-based procedures performed by specialized personnel, utilizing equipment mostly installed in hospitals or research institutions to deliver electro-magnetic energy through the skull.

[0010] Therefore, there are fundamental limitations in terms of accessibility and compliance for patients to apply this repeatedly over a long period and at a high frequency in everyday life. Recently, non-invasive sensory stimulation technologies that aim to regulate brain neural activity by utilizing auditory or visual stimuli in specific frequency bands are being attempted in human studies.

[0011] However, high-intensity light stimulation (flickering) or prolonged noise-induced auditory stimulation causes significant visual-auditory fatigue, discomfort, and stress in elderly patients experiencing cognitive decline.

[0012] In particular, repetitive photostimulation carries potential safety risks that may induce photosensitive seizures in some patients. These safety and tolerability issues represent a fundamental limitation for home care therapeutic devices that must ensure patient compliance and guarantee long-term safety.

[0013] Therefore, there is a very high need for a new type of neural stimulation control device and system with a differentiated structure to overcome the limitations of existing visual-auditory based stimulation and enable patients to use it daily without resistance, based on high safety and comfortable usability.

[0014] As an alternative, some non-pharmacological interventions have been proposed to alleviate symptoms in patients with dementia and cognitive decline by utilizing mechanical vibration or low-frequency vibroacoustic stimulation.

[0015] It has been reported that tactile somatosensory stimulation using low-frequency vibrations in general vibration devices may contribute to emotional stability, alleviation of behavioral and psychological symptoms, and improvement of some cognitive functions.

[0016] However, most conventional vibration devices rely on simple physical impact methods utilizing the eccentric mass of a rotary motor or designs including multiple bolted joint structures, which tend to generate relatively large irregular mechanical-acoustic noise during operation.

[0017] In addition, in this structure, the perceived intensity of the vibration stimulation transmitted to the actual human body is reduced due to pressure during the process in which the vibration probe contacts the scalp, and the efficiency of energy transmitted to the cerebral cortex via the skull is also prone to decrease.

[0018] In particular, considering the complex biomechanical characteristics of the brain, there was a fundamental limitation in that if the applied physical impact energy did not reach a certain level, it failed to induce mechanical resonance in the deep brain tissues, thereby failing to produce macroscopic and significant clinical improvement effects such as protection against structural atrophy of the brain or inhibition of reduced cerebral blood flow.

[0019] Therefore, it is necessary to minimize energy loss and noise during vibration stimulus delivery, while ensuring excellent safety and compliance even in long-term application environments for patients with cognitive impairments or neurodegenerative diseases.

[0020] Furthermore, there is an urgent need to develop a vibration device capable of inducing practical clinical efficacy, an integrated control system, and a method to alleviate brain function decline using these devices, while applying the transcranial acoustic vibration (tVAS) method to directly penetrate mechanical energy into brain tissue through the skull to overcome the limitations of existing indirect sensory synchronization technologies.

[0021] The present invention aims to provide a neural stimulation control device and system including a vibration device that can be utilized for long-term home care, and a method for alleviating brain function decline using the same, by eliminating stress or side effects that may be caused by existing sensory stimulation devices, such as auditory fatigue or the risk of photosensitive seizures, and by providing safe transcranial vibroacoustic stimulation (tVAS) to subjects with cognitive impairment or degenerative neurological diseases.

[0022] The present invention aims to provide a neural stimulation control device and system, and a method for alleviating brain function decline using the same, which includes a comfortable vibration device that reduces discomfort to a subject by minimizing mechanical and acoustic noise generated during operation, by designing the cone damper and bobbin, among the main components constituting the vibration device, as an integrated unit, and by adopting a modular structure in which the vibration probe, the integrated cone damper, and the integrated bobbin are assembled with a single connecting member, thereby facilitating assembly and miniaturizing the device.

[0023] The present invention aims to provide a neural stimulation control device and system, and a method for alleviating brain function decline using the same, comprising a vibration device configured to surround an integrated cone damper and a lower body, etc., with a spring-acting rubber frame, thereby compensating for the conventional limitations in which vibration energy transmitted into the actual human body and vibration tactile sensation intensity are reduced due to a compression phenomenon when a vibration probe comes into contact with the human body (scalp, etc.), and ensuring that a specific frequency effective for treatment is transmitted precisely and stably to the cerebral cortex without loss.

[0024] The present invention aims to provide a neural stimulation control device and system comprising a vibration device having excellent clinical efficacy capable of suppressing abnormal overconnection in low-frequency bands within the brain network and reconstructing the cerebral cortex network into an efficient functional connection structure centered on high-frequency (alpha, beta, gamma) bands, thereby suppressing localized cerebral blood flow reduction in major brain regions including the default mode network (DMN), and physically defending against structural atrophy of core brain structures such as the hippocampus and amygdala, by applying specific frequency and critical acceleration control logic that directly strikes mechanoreceptors within brain tissue and induces macroscopic mechanical resonance based on vibrational energy of a specific frequency efficiently transmitted to the deep brain via the skull through an optimized structure.

[0025] The problems to be solved by the present invention are not limited to those mentioned above, and other problems not mentioned will be clearly understood by those skilled in the art from the description below.

[0026] A neural stimulation control device according to one aspect of the present invention for achieving the above objectives includes a vibration device that applies transcranial vibroacoustic stimulation (tVAS) for improving cognitive function, which is worn on the head of a subject with a cognitive impairment or a degenerative brain neurological disease. The vibration device applies physical transcranial vibroacoustic stimulation having a frequency selected or adjusted for each subject within a range of 20 Hz to 120 Hz to the head of the subject, and can be controlled to a critical acceleration that induces mechanical resonance in the deep brain by penetrating vibration energy, which is a mechanical wave, directly into the brain tissue through the skull to directly strike and stimulate mechanoreceptors within the brain tissue.

[0027] In addition, the frequency selected or adjusted is in the range of 20 Hz to 80 Hz, and the controlled critical acceleration can be set in the range of 0.1 m / s to 7.2 m / s within the limit of eliciting a response from a plurality of the mechanical receivers.

[0028] In addition, the frequency selected or adjusted is in the range of 36 Hz to 44 Hz or 72 Hz to 88 Hz, and the controlled critical acceleration can be precisely adjusted in the range of about 0.25 m / s to about 0.90 m / s including a variation within ±10% to 20%.

[0029] In addition, the vibrational energy accompanied by the controlled critical acceleration can induce mechanical resonance by generating physical tensile force on Piezo1 channels, which are mechanically sensitive ion channels distributed in the cell membrane, thereby inducing structural opening, and being directly transmitted to the brain tissue deep within the brain regardless of whether the phase of the brainwaves is synchronized.

[0030] In addition, the vibration device may further include an assembly module structure having a cone damper and a bobbin formed integrally to minimize mechanical acoustic noise generated during operation.

[0031] In addition, the vibration device may further include a rubber frame that wraps around the assembly module structure and performs a spring action to prevent attenuation of the vibration energy caused by the compression phenomenon that occurs when contacting the scalp of the subject, thereby maintaining the critical acceleration to the cerebral cortex without loss.

[0032] In addition, the mechanical resonance induced by the vibration device can alleviate the progression of total brain volume atrophy in the subject and physically inhibit the progression of anatomical volume reduction in the hippocampus and amygdala located deep in the brain.

[0033] In addition, the transcranial acoustic vibration applied by the vibration device may include a first phase in which the cohesion of the subject's brain network is temporarily increased to activate neuroplasticity during the first to 12 weeks of the stimulation, and a second phase in which functional network reorganization in a specific frequency band is induced during the 13 to 24 weeks of the stimulation.

[0034] In addition, the network realignment of the second phase may be a process of reducing the synchronization of the subject's pathological slow wave Delta band and reorganizing the cerebral cortex network into a functional connectivity structure centered on Alpha, Beta, and Gamma bands.

[0035] In addition, the transcranial acoustic vibration applied by the vibration device can maintain brain metabolic function by inhibiting the progression of local cerebral blood flow reduction in the PCC-Precuneus region and the medial temporal region, which are brain regions including the default mode network (DMN), compared to the control group applied at the critical acceleration.

[0036] In addition, the physical transcranial acoustic vibration accompanied by the controlled critical acceleration is controlled to be applied continuously for at least 30 minutes per session, at least once a day, and can delay the rate of deterioration of the subject's Clinical Dementia Rating Scale (CDR-SB) and Alzheimer's Disease Rating Scale (ADAS-Cog) scores by alleviating brain volume atrophy caused by the penetration of the vibration energy, which is a mechanical wave.

[0037] In addition, the subject with the above-mentioned cognitive impairment or the above-mentioned degenerative neurological disease may be an early-stage Alzheimer's disease patient whose age is 55 years or older and 80 years or younger, whose K-MMSE-2 score is 20 to 28 points, and whose memory item of the CDR-SB score is 0.5 points or 1 point.

[0038] In addition, the above cognitive function disorders may include one or more of attention disorders, persistent attention disorder, attention deficit hyperactivity disorder (ADHD), working memory disorders, episodic memory disorders, executive function disorders, learning disabilities, language disorders, psychomotor disorders, mild cognitive impairment (MCI), and cognitive impairment accompanied by sarcopenia.

[0039] In addition, the above-mentioned degenerative neurological diseases may include one or more of Parkinson's disease, traumatic brain injury (TBI), multiple sclerosis, drug intoxication, alcohol intoxication, brain inflammation, multi-organ atrophy, Huntington's disease, amyotrophic lateral sclerosis (ALS), chronic traumatic encephalopathy (CTE), motor neuron disease, dementia, Creutzfeldt-Jakob disease, and normal pressure hydrocephalus.

[0040] Additionally, the dementia may include one or more of Alzheimer's disease (AD), vascular dementia, Lewy body dementia, frontotemporal dementia (FTD), AIDS-induced dementia, mixed dementia, age-related cognitive impairment, and age-related memory impairment.

[0041] In addition, the vibrational energy, which is a mechanical wave accompanied by the controlled critical acceleration, can activate autophagy in neurons within the brain tissue and inhibit the hyperphosphorylation of Tau protein.

[0042] In addition, the vibrational energy, which is a mechanical wave, can act on microglia within the brain tissue to reduce the expression of neuroinflammatory mediators (IL-1β, TNF-α, IL-6), thereby suppressing neuroinflammation.

[0043] In addition, the transcranial acoustic vibration generated by the vibration device can be controlled with a sound pressure parameter of -0.80 Pa to +0.80 Pa to transmit the vibration energy, which is the mechanical wave, into the brain tissue.

[0044] A neural stimulation control system for improving cognitive function of a subject with a cognitive impairment or degenerative neurological disease according to one aspect of the present invention for achieving the above objectives comprises a vibration device that is worn on the head of the subject and applies physical acoustic vibration, and a control unit that controls the operation of the vibration device, wherein the control unit can drive the vibration device at a frequency selected or adjusted for each subject within a range of 20 Hz to 120 Hz so as to apply transcranial acoustic vibration (tVAS) that penetrates mechanical wave energy directly into the brain tissue through the skull of the subject, and at a critical acceleration that directly strikes and stimulates mechanoreceptors in the brain tissue and induces mechanical resonance in the deep brain.

[0045] In addition, the control unit can drive the vibration device within a frequency of 20 Hz to 80 Hz and a critical acceleration range of 0.1 m / s to 7.2 m / s to the extent that it elicits a response from a plurality of the mechanical receivers.

[0046] In addition, the control unit can drive the vibration device at a frequency of 36 Hz to 44 Hz or 72 Hz to 88 Hz, and generate a control signal by precisely setting the critical acceleration to a range of about 0.25 m / s to about 0.90 m / s including a variation within ±10% to 20% of mechanical tolerance.

[0047] In addition, the mechanical resonance induced by the vibration device according to the control signal of the control unit can alleviate the progression of atrophy of the subject's whole brain volume and induce macroscopic mechanical resonance of the subject's hippocampus and amygdala, thereby physically protecting against pathological atrophy of the limbic system structure.

[0048] In addition, the control unit monitors the operation of the vibration device according to the application period and may be configured to perform a device operation protocol in 24-week units, including a neuroplasticity activation period of weeks 1 to 12 of stimulation application and a brain network realignment period of weeks 13 to 24 of stimulation application.

[0049] In addition, after performing the above 24-week device operation protocol, the device control parameters can be corrected by confirming the effects of protecting against structural brain atrophy and realigning functional networks through brain vMRI, SPECT, and quantitative electroencephalography (QEEG) analysis of the subject.

[0050] A method for alleviating the decline in brain function of a subject with cognitive impairment or degenerative neurological disease according to one aspect of the present invention for achieving the above objectives may be performed by directly striking and stimulating mechanoreceptors within the brain tissue with a frequency selected or adjusted for each subject within a range of 20 Hz to 120 Hz through a vibration device worn on the head of the subject, and applying transcranial acoustic vibration (tVAS) controlled by a critical acceleration that induces mechanical resonance in the deep brain to penetrate directly into the brain tissue through the skull, performing a first step of temporarily increasing the cohesion of the subject's brain network during the initial stimulation period of weeks 1 to 12, and performing a second step of suppressing structural atrophy of the deep brain by inducing functional network reorganization in a specific frequency band during the later stimulation period of weeks 13 to 24.

[0051] Additionally, the applied transcranial acoustic vibration can be controlled within a frequency of 20 Hz to 80 Hz and a critical acceleration range of 0.1 m / s to 7.2 m / s to the extent that it elicits a response from a plurality of the mechanoreceptors.

[0052] In addition, the applied transcranial acoustic vibration is driven at a frequency of 36 Hz to 44 Hz or 72 Hz to 88 Hz, and the critical acceleration can be precisely controlled in a range of about 0.25 m / s to about 0.90 m / s including a variation within ±10% to 20% of mechanical tolerance.

[0053] Additionally, the second step may include a step of strengthening functional connections centered on Alpha, Beta, and Gamma bands centered on the Frontal and Central regions while reducing synchronization of the Delta band.

[0054] In addition, performing the first and second steps may include the step of continuously applying the vibration device at least once a day for at least 30 minutes per session to delay the reduction in local cerebral blood flow in the area including the subject's default mode network (DMN).

[0055] In addition, performing the first and second steps above can lead to a result that significantly delays the rate of deterioration of the subject's Clinical Dementia Rating Scale (CDR-SB) and Alzheimer's Disease Rating Scale (ADAS-Cog) scores compared to the control group by inhibiting the reduction in volume of the subject's hippocampus and amygdala.

[0056] Accordingly, in some embodiments, the present invention provides a neural stimulation control device, system and method applicable to various forms of dementia.

[0057] In terms of device and hardware aspects, the neural stimulation control device, system, and method for alleviating brain function decline using the same, including a vibration device according to the present invention, adopts a modular structure in which a cone damper and a bobbin, among the main components constituting the vibration device, are designed as an integrated unit and assembled with a vibration probe and a single connecting member, thereby enabling the device to be miniaturized and minimizing mechanical-acoustic noise generated during operation to provide comfortable vibration stimulation.

[0058] A neural stimulation control device and system including a vibration device according to the present invention, and a method for alleviating brain function decline using the same, are configured to wrap an integrated cone damper and a lower body, etc., with a rubber frame that acts as a spring, thereby preventing vibration energy attenuation due to compression when in contact with the scalp and stably transmitting energy of critical acceleration effective for treatment to the cerebral cortex without loss.

[0059] A neural stimulation control device and system including a vibration device according to the present invention, and a method for alleviating brain function decline using the same, can fundamentally eliminate side effects such as auditory fatigue, stress, and the risk of photosensitive seizures caused by conventional sensory entrainment methods using high-intensity light flashing or noise, in terms of safety and stimulation transmission mechanism.

[0060] A neural stimulation control device and system including a vibration device according to the present invention, and a method for alleviating brain function decline using the same, can provide a safe and innovative non-drug intervention capable of directly penetrating mechanical wave energy having a frequency and critical acceleration controlled within the range of 20 Hz to 120 Hz into the brain tissue through the skull, thereby directly striking mechanoreceptors within the brain tissue and inducing a mechanical resonance response in the deep brain tissue.

[0061] A neural stimulation control device, system, and method for alleviating brain function decline using the same, including a vibration device according to the present invention, can stably and effectively protect against anatomical atrophy of deep brain structures under precise controlled critical acceleration conditions of 0.25 m / s to 0.90 m / s, according to an embodiment, at a frequency band of 36 Hz to 44 Hz or 72 Hz to 88 Hz.

[0062] A neural stimulation control device and system including a vibration device according to the present invention, and a method for alleviating brain function decline using the same, can not only physically alleviate the progression of irreversible whole brain volume atrophy in degenerative neurodegenerative diseases through induced mechanical resonance in terms of brain structure and metabolic defense, but also defend against the reduction in anatomical volume of the hippocampus and amygdala, which are core memory-regulating regions located deep within the brain.

[0063] A neural stimulation control device and system including a vibration device according to the present invention, and a method for alleviating brain function decline using the same, can maintain brain metabolic function by inhibiting the progression of localized cerebral blood flow reduction in PCC-Precuneus and temporal lobe regions including the default mode network (DMN), which is an Alzheimer's disease vulnerable brain network.

[0064] A neural stimulation control device and system including a vibration device according to the present invention, and a method for alleviating brain function decline using the same, in terms of improving electrophysiological brain networks, transcranial acoustic vibration (tVAS) stimulation can activate neuroplasticity in the early stages and, upon long-term application, reduce abnormal slow wave (Delta / Theta) hypersynchronization patterns unique to patients, and at the same time, efficiently reorganize the functional connectivity structure of the brain around core networks related to high-dimensional cognitive processing, such as alpha, beta, and gamma bands, thereby restoring the information processing ability of the cortical network.

[0065] The neural stimulation control device and system including the vibration device according to the present invention, and the method for alleviating brain function decline using the same, are organically combined with the effects of physical atrophy protection of deep brain tissue, maintenance of blood flow metabolism, and network realignment in terms of final clinical prognosis, thereby statistically significantly delaying the rate of deterioration of Clinical Dementia Rating Scale (CDR-SB) and Alzheimer's Disease Rating Scale (ADAS-Cog) scores, which reflect overall cognitive and functional changes in actual subjects, compared to the control group, and can derive a visible therapeutic prognosis of substantial alleviation of cognitive function decline.

[0066] The neural stimulation control device and system including the vibration device according to the present invention, and the method for alleviating brain function decline using the same, may include a direct energy delivery method in which physical energy penetrates deep into brain tissue and acts directly on the cell membrane, unlike a transcranial acoustic vibration (tVAS) system which may include independence from brainwave synchronization and derive therapeutic effects by forcibly synchronizing brainwaves to a specific frequency through visual / auditory rhythms. In this method, even in the case of non-responders whose brainwaves are not synchronized with external stimuli, the physical stimulation applied to the cell membrane remains unchanged, thereby enabling therapeutic effects; and since it is delivered directly through the skull and bone conduction pathways without passing through sensory organs (ears, eyes), the same energy can be projected even to elderly patients with reduced auditory or visual function; and unlike brainwave synchronization which is mainly limited to the electrical activity of the cerebral cortex, physical vibrations can be directly delivered to deep brain structures such as the hippocampus and amygdala through critical acceleration-based vibrations to suppress anatomical atrophy.

[0067] The effects of the present invention are not limited to those mentioned above, and other unmentioned effects will be clearly understood by those skilled in the art from the description throughout the specification.

[0068] FIG. 1 is a perspective view illustrating a vibration device according to the present invention.

[0069] FIGS. 2 and FIGS. 3 are exploded views illustrating a vibration device according to the present invention.

[0070] FIGS. 4 and FIGS. 5 are cross-sectional views of a vibration device according to the present invention.

[0071] FIG. 6 is a cross-sectional view showing the upper and lower spring action of the rubber frame of the present invention.

[0072] FIGS. 7 to 10 are drawings showing the configuration of a neural stimulation control device including a vibration device according to the present invention.

[0073] FIG. 11 is a block diagram showing the configuration of the neural stimulation control device of FIG. 7 to FIG. 10.

[0074] FIGS. 12 and 13 are drawings illustrating the experimental design used in the experimental example of the present invention and the provision of vibratory tactile sensation to experimental mice through a neural stimulation control device.

[0075] Figure 14 is a graph showing the change in body weight of a mouse in an experimental example of the present invention.

[0076] Figure 15 is a graph showing the step delay times in a passive avoidance test of a rat in an experimental example of the present invention.

[0077] Figure 16 is a graph showing the escape delay time in a water maze test of a rat in an experimental example of the present invention.

[0078] Figure 17 shows photographs of the overall shape of a mouse brain in an experimental example of the present invention.

[0079] Figure 18 shows photographs of the overall shape of a rat's adrenal gland in an experimental example of the present invention.

[0080] Figure 19 is a graph showing serum corticosterone levels in rats in an experimental example of the present invention.

[0081] Figure 20 is a graph showing the hippocampal Ach content of a rat in an experimental example of the present invention.

[0082] Figure 21 is a graph showing the hippocampal AchE content of a mouse in an experimental example of the present invention.

[0083] Figure 22 is a representative histopathological image of the mouse brain-hippocampus in an experimental example of the present invention.

[0084] Figure 23 is a representative image of caspase-3 immunolabeled pyramidal cells in the brain-hippocampus DG region of a mouse in an experimental example of the present invention.

[0085] Figure 24 is a representative image of c-Fos immune-positive pyramidal cells in the brain-hippocampus DG region of a mouse in an experimental example of the present invention.

[0086] Figure 25 is a representative histopathological image of a rat's adrenal gland in an experimental example of the present invention.

[0087] FIGS. 26 to 30 relate to experimental examples of cell experiments of the present invention, and include a diagram of the cell experiment configuration for acoustic vibration, a conceptual diagram schematically explaining the overall contents of the acoustic vibration cell experiment, and graphs showing the experimental results.

[0088] FIG. 31 is a schematic diagram showing the characteristics and assignment status of subjects in a clinical trial according to the present invention.

[0089] FIG. 32 is a table showing a summary of adverse events (AE) observed during the clinical trial process according to the present invention.

[0090] FIGS. 33 to 35 are graphs showing the effect of alleviating structural volume atrophy of the total brain volume, hippocampus, and amygdala through brain MRI analysis according to the present invention.

[0091] Figure 36 is a graph showing the local cerebral blood flow protection effect of major brain regions (PCC Precuneus, Lateral Parietal, Lateral Temporal, and Medial Temporal) through brain SPECT according to the present invention.

[0092] Figure 37 is a graph showing the change amount relative to the baseline of the Clinical Dementia Rating Scale (CDR-SB) among the clinical cognitive function evaluation scales according to the present invention.

[0093] Figure 38 is a graph showing the change from baseline of the Alzheimer's disease assessment scale (ADAS-K-Cog 13) among the clinical cognitive function assessment scales according to the present invention.

[0094] FIGS. 39 to 41 show the results of quantitative electroencephalography (QEEG) analysis according to the present invention, where FIG. 39 shows the change in spectrum characteristics (Topoplot) by frequency band, FIG. 40 shows the change in coherence matrix, and FIG. 41 shows the result of restructuring the functional connectivity map structure.

[0095] Terms and words used in this specification and claims should not be interpreted as being limited to their ordinary or dictionary meanings, but should be interpreted in a meaning and concept consistent with the technical spirit of the invention, based on the principle that the inventor can appropriately define the concept of the terms to best describe his invention.

[0096] 1. Definition of Terms

[0097] Unless otherwise specifically noted in this specification, the definitions of key terms used are as follows.

[0098] "Individual" or "Subject": Refers to a mammal, e.g., a rodent, cat, dog, or primate, for which prevention, alleviation, or treatment of a disease, disability, or condition is required. Preferably, the individual according to the present invention is a human. In this specification, the term collectively refers to a patient suffering from a cognitive impairment, including mild cognitive impairment (MCI), or a neurodegenerative disease, including early Alzheimer's disease (AD).

[0099] "Treatment" and "Relief": Refers to any medical or physical approach aimed at obtaining beneficial or desirable results, including clinical outcomes. For the purposes of this invention, "treatment" is used in a broad sense that goes beyond mere symptom relief to include the delay of disease progression, physical protection against atrophy of total brain volume and deep brain structures, inhibition of localized cerebral blood flow reduction, and substantial alleviation of cognitive decline through the functional realignment of cortical networks.

[0100] "Dementia" or "degenerative neurological disease": Refers to a comprehensive group of diseases in which multiple cognitive function impairments, such as memory and judgment, occur due to damage or destruction of brain cells. In the present invention, this includes Alzheimer's disease (AD), vascular dementia, frontotemporal dementia (FTD), Lewy body dementia, Parkinson's disease, and the like.

[0101] "About" or "approximately": Used to encompass the range of error ordinarily accepted in the art with respect to specified figures or ranges. For example, it is interpreted as a concept including a variation within ±10% to 20%, which is a mechanical tolerance, with respect to the frequency (e.g., 40Hz, 20Hz) or critical acceleration value applied by the device of the present invention.

[0102] "Transcranial Vibroacoustic Stimulation (tVAS)": Refers to a non-invasive physical stimulation method unique to the present invention that directly penetrates mechanical wave energy into the brain tissue through the skull.

[0103] "Critical Acceleration" and "Mechanical Resonance": These refer to a specific acceleration threshold capable of reaching deep brain tissues (hippocampus, amygdala, etc.) beyond simple skin stimulation to exert a macroscopic physical impact effect, thereby inducing a mechanical resonance phenomenon that physically inhibits pathological brain volume atrophy.

[0104] "Cerebral Cortical Network Reorganization": This refers to the phenomenon in which the functional connectivity of the brain, which has collapsed due to degenerative neurological diseases, is reorganized into an efficient structure through the vibrational stimulation of the present invention. Specifically, it refers to the process in which pathological slow-wave synchronization is reduced and the connectivity is organized around high-frequency (Alpha, Gamma) core networks.

[0105] "Quantitative Electroencephalography (QEEG)": Refers to an analysis method that measures the brain's spontaneous electrical activity (resting brainwaves) to mathematically quantify and visualize the spectral characteristics of each frequency band (Delta, Theta, Alpha, Beta, Gamma).

[0106] "Coherence" and "Functional Connectivity": These are brain network analysis indicators that represent how strongly signals between brain regions (channels) are synchronized and functionally connected.

[0107] "EEG slowing": Refers to a representative pathological brainwave pattern in Alzheimer's disease patients that reflects the decline in brain network function, characterized by an abnormal increase in low-frequency bands (Delta, Theta) and a decrease in high-frequency bands.

[0108] "Default Mode Network (DMN)": A core network of the brain that is activated in a resting state without focusing on external tasks, and includes vulnerable areas (such as the PCC-Precuneus and medial temporal lobe) where early reductions in metabolism and blood flow are prominent in Alzheimer's disease.

[0109] “Clinical cognitive function assessment scales (CDR-SB and ADAS-K-Cog 13)”: These are scales used to evaluate the clinical efficacy of subjects. CDR-SB indicates the overall degree of dementia progression, such as memory, judgment, and ability to perform daily activities, while ADAS-K-Cog 13 refers to a core assessment tool that comprehensively quantifies various cognitive domains, such as memory, language ability, and executive function.

[0110] 2. Definition of Subjects and Scope of Applicable Diseases

[0111] A neural stimulation control device and system including a vibration device according to the present invention, and a method for alleviating brain function decline using the same, may be used to alleviate or treat diseases related to cognitive impairment, but are not limited thereto.

[0112] For example, a neural stimulation control device, system including a vibration device according to the present invention, and a method for alleviating brain function decline using the same may be used for the prevention, alleviation, or treatment of symptoms of cognitive impairment, and the symptoms of cognitive impairment may be selected from the group consisting of reduced attention, reduced language ability, reduced visuospatial ability, reduced reasoning ability, and reduced judgment ability.

[0113] Diseases related to cognitive impairment include mild cognitive impairment, Alzheimer's disease, Alzheimer-type dementia, presenile dementia, early-onset Alzheimer's disease, senile dementia, Dementia with Lewy bodies (DLB), Parkinson's disease (PD), micro-infarct dementia, AIDS-related dementia, HIV-dementia, Down's syndrome-associated dementia, Pick's disease, recent short-term memory impairment, age-associated cognitive disorder, age-associated memory impairment, drug-associated cognitive disorder, immunodeficiency syndrome-associated cognitive disorder, and vascular disease-associated cognitive disorders. Disorder (vascular disease-associated cognitive impairment), cognitive impairment associated with schizophrenia, cognitive impairment associated with Parkinson's disease, Parkinson's Disease Dementia,Cognitive disorders associated with epilepsy, depression-associated cognitive disorder, cognitive disorders associated with bipolar disorder, obsessive-compulsive disorder-associated cognitive disorder, post-traumatic stress disorder, attention deficit disorder, attention deficit hyperactivity disorder, learning deficit disorder, and additional conditions including frontotemporal dementia (FTD), progressive supranuclear palsy (PSP), multiple sclerosis (MS), Huntington's disease (HD), vascular dementia (VaD), traumatic brain injury (TBI), multi-infarct dementia, and cerebral amyloid Cerebral Amyloid Angiopathy, stroke and post-stroke recovery, cerebral small vessel disease, mixed dementia, Multiple System Atrophy (MSA), Down's Syndrome (DS) and Down's Syndrome-associated dementia,It may be selected from, but is not limited to, the group consisting of Amyotrophic Lateral Sclerosis (ALS), Apolipoprotein E4 homozygous condition, depression: Major Depressive Disorder (MDD), Geriatric Depression, Agitation Symptoms Associated with Dementia due to Alzheimer's Disease, and Schizophrenia.

[0114] Dementia is a disorder characterized by the loss of intellectual ability and / or memory impairment. Depending on its causes and characteristics, dementia broadly encompasses Alzheimer's disease (AD), vascular dementia, Lewy body dementia, Pick's disease, frontotemporal dementia (FTD), AIDS dementia, age-related cognitive impairment, and age-related memory impairment.

[0115] Dementia can manifest in association with various neurological and psychiatric conditions such as brain tumors, brain lesions, epilepsy, multiple sclerosis, Down syndrome, Rett syndrome, progressive supranuclear palsy, frontal lobe syndrome, schizophrenia, and traumatic brain injury (TBI).

[0116] The specific characteristics of major degenerative neurological diseases are as follows.

[0117] 1) Alzheimer's disease (AD): It is the most frequent neurodegenerative disease in developed countries. Pathologically, it is initiated by the accumulation of amyloid plaques composed of neurofibrillary tangles (NFTs) made of Aβ peptides and tau proteins, ultimately leading to disruption of brain networks and macroscopic brain volume atrophy. Clinically, AD is associated with progressive cognitive impairment characterized by the loss of memory, function, language ability, judgment, and executive function, and causes severe behavioral symptoms in advanced stages.

[0118] 2) Vascular Dementia: Also referred to as cerebrovascular dementia, it is caused by cerebrovascular disease (e.g., infarction of the cerebral hemispheres). It generally follows a course that fluctuates between periods of improvement and staged deterioration. It is accompanied by disorientation, impaired memory, and impaired judgment, and can be caused by various vascular factors including multiple infarctions, systemic lupus erythematosus, infectious vasculitis (Lyme disease), recurrent intracerebral hemorrhage, and stroke.

[0119] 3) Frontotemporal dementia (FTD): A progressive neurodegenerative disorder accompanied by atrophy of the frontal and temporal lobes. Individuals with FTD are typically characterized by exhibiting prominent behavioral and personality changes, often accompanied by language impairment, before memory decline.

[0120] 4) Lewy Body Dementia: Characterized by one or more symptoms of dementia development that overlap with traits of AD, Parkinson's disease, and early hallucination development. This disease is generally characterized by large daily fluctuations in the severity of symptoms.

[0121] The cognitive functions associated with the aforementioned brain disorders and dementia are related to the balance of brain neural network activity across various frequency bands, and abnormal changes in neural rhythms associated with attention and working memory may appear as one of the major characteristics of cognitive decline.

[0122] Therefore, non-invasively restoring (acting on) high-frequency brain rhythms and realigning cerebral cortical networks through the transcranial acoustic vibration (tVAS) device, system, and method of the present invention plays an excellent role as a multi-target therapy for preventing, alleviating, and treating various forms of dementia, including Alzheimer's disease.

[0123] 3. Vibration Device Module Structure

[0124] FIG. 1 is a perspective view illustrating a vibration device according to the present invention. FIG. 2 and FIG. 3 are exploded views illustrating a vibration device according to the present invention. FIG. 4 and FIG. 5 are longitudinal cross-sectional views of a vibration device according to the present invention. FIG. 6 is a cross-sectional view showing the upper and lower spring action of a rubber frame according to the present invention.

[0125] Referring to FIGS. 1 to 6, the nerve stimulation control device according to the present invention is equipped with a vibration device (100) to provide stimulation by vibration tactile sensation. The vibration device (100) according to the present invention may be configured to include a vibration probe (120), an integrated cone damper (130), an integrated bobbin (140), a lower body (160), a magnetic body (150), a cap magnetic body (155), and a rubber frame (170).

[0126] The vibration probe (120) transmits vibration tactile sensations generated from the vibration device (100) to the outside to stimulate nerves through the skin or scalp of the human body, and may include a plate portion (121), a coupling projection portion (123) protruding from the lower surface of the plate portion (121), and a first through hole (121a) penetrating the center of the plate portion (121) and the coupling projection portion (123).

[0127] The plate portion (121) may have a plurality of circular grooves (121b) formed concentrically around a first through hole (121a) on its upper surface, and the circular grooves (121b) may reduce the contact surface with the body while increasing the vibration tactile transmission rate or intensity at the contact surface.

[0128] The connecting projection (123) is formed with a tapered structure that narrows as it goes downward from the plate portion (121), and a first contact end (124) that contacts one surface of the cone plate (135) may be provided at the lower end.

[0129] The integrated cone damper (130) may include a body portion (131) in the shape of a tube and a cone plate (135) in which a rim area is inserted along the circumferential direction from the upper part of the body portion (131) and a hollow hole (135a) is formed.

[0130] For example, the cone plate (135) may be exemplified as being joined by insert injection molding on the inner surface of the body portion (131). The body portion (131) may have a pair of cut portions (132) formed to have an elastic structure in a facing position, and a catch projection (132a) may be formed on the inner surface of the cut portions (132).

[0131] A mounting portion (133) is installed on one side of the outer surface of the body portion (131), and a board (137) that outputs a signal input from the outside (AMP, etc.) to a bonding type voice coil (145) may be mounted thereon. An input line and an output line may be connected to the board (137).

[0132] The cone plate (135) serves to generate vertical vibrations using a magnetic field generated by the interaction between the magnetic body (150) and the voice coil (145), and may be structured such that a plurality of damper parts (135b) extend from the hollow hole (135a) toward the edge.

[0133] The integrated bobbin (140) is received within the integrated cone damper (130) and may include a support plate portion (141), a coupling portion (143) formed protruding from the upper surface of the support plate portion (141) and having a second through hole (141a) formed therein, and a bonding type voice coil (145) coupled to the lower surface of the support plate portion (141).

[0134] The voice coil (145) can generate a magnetic field by receiving power and interacting with the magnetic body (150). The coupling portion (143) may be provided with a second contact end (143a) at its upper end that contacts the lower surface of the cone plate (135), and an insertion end (143b) that extends from the second contact end (143a) and is sequentially inserted into the hollow hole (135a) and the first through hole (121a).

[0135] The bonding type voice coil (145) may be characterized by being manufactured in the shape of a mini tube using adhesive resin, unlike the wound type voice coil which is manufactured by winding directly onto a bobbin.

[0136] The bonding type voice coil (145) can be inserted into the circular groove (141b) formed on the lower surface of the support plate (141) and then fixed with adhesive or the like. The integrated bobbin (140) can be manufactured to be small compared to a general bobbin and a wound type voice coil, and can provide a structure that can stabilize heat generation due to vibration at a rated output of 0.5W by changing the impedance from 3.3Ω to 8Ω.

[0137] The present invention may be characterized by a modular structure in which a vibration probe (120), an integrated cone damper (130), and an integrated bobbin (140) are assembled through a single connecting member (110).

[0138] Due to this modular structure, the assembly process can be simplified and the product can be miniaturized. The connecting member (110) may be exemplified as a hexagonal wrench bolt having male threads formed on its outer surface, and while fastened to the female threads formed in the first through hole (121a) provided in the vibration probe (120), it passes through the hollow hole (135a) formed in the integrated cone damper (130) and can be fastened to the female threads formed in the second through hole (141a) provided in the integrated bobbin (140).

[0139] The first contact end (124) and the second contact end (143a) may be configured to have the same outer diameter, and the first through hole (121a) may have an inner diameter larger than that of the second through hole (141a). In this case, the connecting member (110) may be exemplified as being composed of a first male screw thread (112) extending from the head portion (111) and having an outer diameter corresponding to the first through hole (121a), and a second male screw thread (113) extending from the first male screw thread (112) and having an outer diameter corresponding to the second through hole (141a).

[0140] A coupling structure through such a single connecting member (110), that is, the connecting member (110) is sequentially coupled to the first through hole (121a) of the vibration probe (120), the hollow hole (135a) of the integrated cone damper (130), and the second through hole (141a) of the integrated bobbin (140), and at the same time, the second contact end (143a) formed on the upper end of the coupling part (143) of the integrated bobbin (140) is inserted into the first through hole (121a) of the vibration probe (120) and screw-coupled, and the first contact end (124) of the vibration probe (120) and the second contact end (143a) of the integrated bobbin (140), having corresponding outer diameters, are in contact with each other with the hollow hole (135a) in between, so a vibration tactile sensation with minimized noise generation can be output.

[0141] The lower body (160) is detachably fitted and coupled to one side of the body portion (131) of the integrated cone damper (130), and is shaped like a tube with a completely open upper side and a bottom surface (162) formed with a through hole (162a) in the center on the lower side, and may have a receiving space inside.

[0142] A lower body (160) has a magnetic body (150) and a catch groove (161) formed along the circumferential direction on the outer surface of one end, and the catch groove (161) can be coupled to a catch projection (132a) formed on the body part (131) of the integrated cone damper (130).

[0143] The magnetic body (150) is fixedly installed on the bottom surface of the lower body and can interact with the voice coil (145) to generate a magnetic field. The magnetic body (150) can be exemplified as a permanent magnet made of a ferromagnetic material, such as a neodymium magnet.

[0144] The cap magnetic body (155) is fixedly installed on the upper surface of the magnetic body (150) and can serve to induce the magnetic force of the magnetic body (150) to be concentrated on the bonding type voice coil (145). The rubber frame (170) is intended to compensate for the vibration stimulation reduced by the vibration probe (120) being pressed by contact with the human body through a spring action, and can be formed in a tubular shape with one side completely open so as to be fitted and wrapped around the body part (131) and the lower body (160).

[0145] The rubber frame (170) supporting the module structure of the vibration device (100) may be formed of silicone rubber material. The rubber frame (170) can function as an elastic support structure to minimize attenuation of vibrations generated in the module structure of the vibration device (100) due to pressure from contact with the human body and to stably transmit vibration energy.

[0146] The rubber frame (170) can be configured to be interposed between the module structure of the vibration device (100) and the enclosure (outer housing) to reduce structural transmission noise by mitigating the direct transmission of mechanical vibrations generated in the module structure of the vibration device (100) to the enclosure.

[0147] The rubber frame (170) can be formed of a silicone elastomer having a hardness of about 55 to 65 based on Shore A, and this hardness range can effectively absorb and restore mechanical vibrations generated when the module structure of the vibration device (100) is driven, thereby enabling stable vibration transmission for a specific frequency band such as 40 Hz.

[0148] The rubber frame (170) can be formed to have mechanical properties of a tensile strength of about 7 MPa or more, an elongation of about 200% or more, and a tear strength of about 18 N / mm or more. These mechanical properties can prevent structural deformation or breakage even with repeated vibration action of the module structure of the vibration device (100), thereby significantly improving the durability of the device.

[0149] At least one pair of elastic guide grooves (171) may be formed along the longitudinal direction at opposing positions on the outer surface of the rubber frame (170) to facilitate fitting to the body part (131) and the lower body (160).

[0150] An elastic member (173) that acts as a spring in the up and down direction may be formed on the other side of the rubber frame (170). When viewed in terms of the longitudinal cross-sectional structure, the elastic member (173) may be composed of a connecting cross-section (173a) extending from the inner circumference of the other side, a first inclined cross-section (173b) extending downwardly from the connecting cross-section (173a), a second inclined cross-section (173c) extending upwardly from the first inclined cross-section (173b), a horizontal cross-section (173d) extending horizontally from the second inclined cross-section (173c), and a lower edge cross-section (173e) protruding to the other side from the boundary between the first inclined cross-section (173b) and the second inclined cross-section (173c).

[0151] In the elastic part (173), a central space (173f) divided into a lower edge section (173e), a second inclined section (173c), and a horizontal section (173d), and an outer space (173g) divided into a first inclined section (173b) and a second inclined section (173c) may be formed.

[0152] The above cross-sections are three-dimensional geometric structures rotated around a virtual central axis of the rubber frame (170). An opening (172) may be formed in the rubber frame (170) to expose the substrate (137) to the outside when fitted into the integrated cone damper (130).

[0153] 4. Appearance and Control System Configuration of the Neural Stimulation Modulator

[0154] FIGS. 7 to 10 are drawings showing the configuration of a neural stimulation control device including a vibration device according to the present invention. FIG. 11 is a block diagram showing the configuration of the neural stimulation control device of FIGS. 7 to 10.

[0155] Referring to FIGS. 7 to 11, the external shape (main body) of a neural stimulation control device (1) including a vibration device according to an embodiment of the present invention and the configuration of the entire control system are illustrated.

[0156] When looking at the configuration of the main body (hairband) of the neural stimulation control device (1), the neural stimulation control device (1) may be configured to include a main body (10) that is worn so as to be in close contact with the subject's head area, specifically the frontal lobe and temporal lobe areas, and a head fixing band (20) to prevent the main body (10) from slipping down.

[0157] On the front of the main body (10), a display unit (RGB LED, 11) is provided to visually display the operating status of the neural stimulation control device (1), and on the side, a power / mode operation button (12) for controlling the power on / off and acoustic vibration mode of the neural stimulation control device (1) and an intensity operation button (13) for adjusting the vibration intensity to multiple levels (e.g., weak, medium, strong) may be provided.

[0158] A plurality of vibration generating units (30) for directly applying acoustic vibrations to the frontal and temporal lobe regions of the subject are built into the bottom or inside of the main body (10), and a charging terminal (USB C-Type, 14) for charging the built-in battery may be provided. A vibration device (100, see FIG. 1) may be built into the interior of the vibration generating unit (30).

[0159] In particular, the vibration generating part (30) can be configured such that an elastic member made of silicone material (silicone pad, 31) is interposed in the part that contacts the subject's head (scalp) to prevent scalp damage, and at the same time, the acoustic vibration stimulation generated by the nerve stimulation control device (1) can be efficiently and safely transmitted into the brain tissue without loss.

[0160] The configuration of the entire control system according to an embodiment of the present invention is as follows. The neural stimulation control device (1) of the present invention may be composed of an integrated system including a power supply unit (40), a control unit (50), an operation unit (12, 13), an output unit (60), a vibration generating unit (30), and a display unit (11).

[0161] The AC power supplied from the external power supply unit (AC-DC Adapter, 40) can be charged to the internal power source (42) through the charging unit (41). The DC power supplied from the internal power source (42) can be converted to an internal operating voltage of DC 3.3V through a Buck-Boost IC and stably supplied to the control unit (50).

[0162] The control unit (50) can serve as a main board that controls and processes the overall operation of the sound source processing unit (2). The control unit (50) can be configured to receive user input signals from the operation unit (12, 13) and execute commands corresponding to the input signals.

[0163] The control unit (12, 13) includes a plurality of tact switches corresponding to external buttons, and when a user operates a switch, the corresponding input signal can be transmitted to the control unit (50).

[0164] The control unit (50) can control the output unit (60) according to a command input from the operation unit (12, 13) to drive the vibration generating unit (30). The output unit (60) includes an audio amplifier and can amplify the signal transmitted from the control unit (50) to drive the vibroacoustic module of the vibration generating unit (30).

[0165] The vibration generating unit (30) includes a plurality of vibration devices (100) and can generate a vibration signal having a specific frequency and critical acceleration according to a signal transmitted from the control unit (50).

[0166] The vibration generating unit (30) may be configured to transmit vibrations to the user's head area by interposing an elastic member (31) made of silicone material. The vibration generating unit (30) is precisely positioned in the user's frontal and temporal lobe regions, and the mechanical vibration energy generated from the vibration device (100) is transmitted through the elastic member (31) made of silicone material, thereby providing effective acoustic vibration stimulation into the user's brain tissue.

[0167] The control unit (50) can control the display unit (11) to intuitively display the operating status of the neural stimulation control device (1). The display unit (11) includes a plurality of RGB LEDs and, according to a control signal received from the control unit (50), changes the color (e.g., cyan, white, purple, red, etc.) and lighting pattern of the LEDs to clearly and visually display to the user the overall operating status of the neural stimulation control device (1), such as power status, standby mode, acoustic vibration playback mode, and battery charging requirement status.

[0168] The term "about" as used in the present invention may mean within 10%, preferably within 5%, and more preferably within 1% of a given numerical value or range. In one embodiment of the present invention, the present invention may provide a neural stimulation control device, method, and system for inducing vibrational stimulation.

[0169] The neural stimulation control device, method, and system according to the present invention can induce vibration stimulation of about 20 to about 120 Hz, preferably about 20 to 80 Hz, e.g., about 20, 30, 40, 50, 60, 70, or 80 Hz. Most preferably, it may induce vibration stimulation of about 40 Hz or about 80 Hz.

[0170] The present invention may include an 80Hz natural frequency as a core stimulus parameter to overcome the sensory adaptation and sensory organ dependence associated with 40Hz stimulation. The 80Hz frequency may have a stronger characteristic of physical energy projection transmitted as wave energy within biological tissues than a characteristic as a rhythm perceived in the cerebral cortex.

[0171] According to experimental results, vibrations in the 80Hz band transmit micro-vibrational energy of the cell membrane more than twice as efficiently as those in the 40Hz band, and in particular, can generate optimal mechanical displacement that exceeds the opening and closing threshold of channels such as Piezo1.

[0172] 80Hz is characterized as a specific frequency band of non-synchronized mechanical stimulation that can induce the expression of neuroprotective proteins even in an environment where sensory synchronization does not occur, as the frequency range is separated from the gamma wave synchronization (40Hz) of the cerebrum.

[0173] The stimulation according to the present invention can be designed to directly strike and stimulate mechanoreceptors (e.g., receptors that detect mechanical stress and / or tension) within the skull and brain tissue in the internal brain region of the subject.

[0174] The threshold or control range of mechanical energy required to elicit a response from receptors and induce mechanical resonance in the deep brain can be adjusted in multiple steps based on the individual sensitivity of the subject within a wide range of about 0.1 m / s to about 10.6 m / s, depending on the embodiment.

[0175] Preferably, the critical acceleration can be set within the range of 0.1 m / s to 7.2 m / s to the extent that it elicits a response from a number of mechanoreceptors. Most preferably, the critical acceleration can be precisely controlled within the range of about 0.25 m / s to about 0.90 m / s, including a variation within ±10% to 20% of mechanical tolerance, in order to induce mechanical resonance in the cerebral cortex and deep brain tissues while maximizing safety.

[0176] The neural stimulation control device (1) according to the present invention may include a critical acceleration control logic for delivering effective energy to deep brain tissues, rather than simply applying vibrations.

[0177] Brain tissue is a viscoelastic medium and may have the characteristic of rapidly attenuating external vibration energy as it passes through the skull and cerebrospinal fluid. In order to overcome this attenuation and physically open channels such as Piezo1, the present invention may control the acceleration measured at the tip of the vibration probe (120) of the vibration device (100) to maintain a critical acceleration in the range of at least 0.25 m / s to 0.90 m / s.

[0178] Unlike acoustic stimulation that simply presents sound, such acceleration control projects actual physical force onto brain cells to induce direct cell membrane deformation; this can be an essential requirement for physical therapy that operates independently of changes in brainwave electrical rhythms. However, this is not limited to this, and the range of critical acceleration can be set to various ranges within the limits of eliciting responses from multiple receptors.

[0179] The vibration of the neural stimulation control device (1) according to the present invention can have a sound pressure in the range of -2.00 Pa to +2.00 Pa to transmit mechanical wave energy into brain tissue, and can be precisely controlled with a sound pressure parameter of at least -1.50 Pa to +1.50 Pa, most preferably at least -0.80 Pa to +0.80 Pa.

[0180] Stimulation by physical acoustic vibration according to the present invention can be performed in a brain region-specific manner. Unlike indirect sensory stimulation, direct mechanical wave energy according to the present invention can reach not only the frontal and temporal cortices of the brain, but also the hippocampus and amygdala, which are core deep structures responsible for memory management, and can strongly activate structural atrophy defenses in those regions.

[0181] That is, the neural stimulation control device (1) according to the present invention may be characterized by a mechanical signal transmission mechanism that applies direct physical deformation to the cell membrane inside the brain tissue, in addition to an indirect method of inducing brain waves through the cognitive process of sensory organs such as sight or hearing.

[0182] Specifically, the applied acoustic vibration energy penetrates the skull and reaches nerve cells or microglia membranes deep within the brain, and at this time, can generate physical tensile force on mechanically responsive ion channels distributed in the cell membrane, particularly channels such as Piezo1.

[0183] Such physical stimulation induces the structural opening of channels such as Piezo1, thereby facilitating the influx of calcium ions into the cell; through this, it can form an independent therapeutic pathway that directly induces protein metabolism and immune activity at the cellular level, regardless of brainwave phase synchronization.

[0184] In addition to the interface for emitting such precise stimulation, the neural stimulation control system of the present invention may be further enhanced by including various electronic components. Specifically, the control unit (50) of the neural stimulation control device (1) may be configured to further include at least one processor (e.g., for calculating vibration patterns according to critical acceleration, controlling the emission of stimulation, and monitoring the operating state), at least one memory (e.g., for storing device operation protocols in 24-week units, acceleration calculation policies, user feedback, etc.), at least one communication interface (e.g., for communicating with a database of subjects, healthcare providers, clinical research investigators, or smart device monitoring applications, etc.), and / or a detection device (e.g., for detecting scalp contact status, brainwave feedback of subjects, safety, etc.).

[0185] 5. Application Time and Treatment Schedule of Non-invasive Nerve Stimulation

[0186] In an embodiment according to the present invention, the subject may receive transcranial acoustic vibration (tVAS) stimulation for various periods of time according to the severity of the disease and individual compliance through a neural stimulation control device (1) according to the present invention.

[0187] The duration of a single stimulus application can be adjusted from minutes to hours, and specifically, the stimulus can be applied for up to 6 hours, up to about 5 hours, up to about 4 hours, up to about 3 hours, up to about 2 hours, or up to about 1 hour.

[0188] Most preferably, in order to efficiently induce mechanical resonance in the deep brain tissues while minimizing the subject's fatigue, physical stimulation accompanied by a specific critical acceleration (0.25 to 0.90 m / s²) may be provided intensively for a period of about 10 to 30 minutes per session.

[0189] The number of times (frequency) of neural stimulation applied according to the present invention can be flexibly set according to the subject's symptoms and condition. For example, it can be applied at various cycles, such as once a day, multiple times (two or more times a day), or three to five times a week, and it may be recommended to apply it regularly every day (e.g., once a day) as a home care device in an everyday life environment to maintain brain neuroplasticity and maximize clinical efficacy.

[0190] In terms of the total duration of treatment, the subject may receive the method provided in the present invention for a short period (e.g., 28 consecutive days) and undergo a long-term treatment schedule that continues for a medium to long period (e.g., 12 weeks, 24 weeks, or 52 weeks or more) to suppress pathological structural changes.

[0191] In particular, subjects may receive stimulation on a regular schedule, such as a systematic device operation protocol on a 24-week basis, or undergo intermittent treatment at specific times when symptoms of cognitive decline occur or worsen. The application of such long-term and regular physical vibration stimulation can have excellent effects in suppressing abnormal slow-wave (delta band) hypersynchronization within the brain networks of early-stage Alzheimer's patients and significantly alleviating the progression of anatomical atrophy of deep brain structures (hippocampus, amygdala) and total brain volume on a macroscopic level.

[0192] In one aspect, the stimulation provided by the present invention may be entirely non-invasive. As used herein, the term "non-invasive" may refer to devices, methods, and systems that do not require any surgical intervention of the body, for example, the injection or implantation of any chemical composition or device into the brain.

[0193] Specifically, unlike conventional indirect sensory entrainment methods that rely on light flashing or noise, the non-invasive stimulation of the present invention may be characterized by mechanical / physical impact using force, vibration, or kinetic energy that penetrates directly into brain tissue through the skull.

[0194] [Example 1]

[0195] - Experimental animals

[0196] A total of 110 6-week-old male SPF / VAF Inbred C57BL / 6NCrlOri mice [OrientBio, Seungnam, Korea] were acclimatized to the laboratory environment for 7 days. Based on body weight (average body weight 20.60 ± 0.93g, 18.80–23.00g) and behavioral status, they were divided into 20 mice per group, comprising a total of 5 groups (Table 1) for use in the experiment. All experimental animals were handled in accordance with the standards of animal ethics under the prior approval of the Daegu Hani University Animal Ethics Committee.

[0197] - Group separation (Total 5 groups; 20 animals per group)

[0198] Normal media control group (medium oral and intraperitoneal administration control group)

[0199] SCP control group (medium oral and SCP intraperitoneal administration control group)

[0200] HVSS20 (20Hz vibratory tactile stimulation and SCP intraperitoneal administration experimental group)

[0201] HVSS40 (40Hz vibratory tactile stimulation and SCP intraperitoneal administration experimental group)

[0202] HVSS80 (80Hz vibratory tactile stimulation and SCP intraperitoneal administration experimental group)

[0203] - Experimental Method

[0204] 1. Causes memory impairment

[0205] According to the method for inducing an animal model of memory impairment commonly used in this field, SCP hydrobromide (Sigma-Aldrich, St. Louis, MO, USA) was dissolved in physiological saline at a concentration of 0.1 mg / ml, and memory impairment was induced by intraperitoneal injection into the right lower abdomen using a 1 ml syringe equipped with a 26 G needle at a dose of 10 ml / kg (1 mg / kg) one hour after vibratory tactile stimulation on days 7, 14, and 28. In the normal media control group, to apply the same administration and correction stress, only the same volume of sterile physiological saline was administered intraperitoneally in the same manner for the same period instead of the SCP solution.

[0206] 2. Vibro-tactile stimulation

[0207] FIGS. 12 and 13 are drawings illustrating the experimental design used in the experimental example of the present invention and the provision of vibratory tactile sensation to experimental mice through a neural stimulation control device.

[0208] Referring to Figures 12 and 13, based on a conventional protocol for evaluating the neuroprotective effect of vibration stimulation, vibration tactile stimulation at 20, 40, or 80 Hz was applied for 10 minutes once daily for 28 days using an HVSS including a cylindrical acrylic cylinder mouse restraint device (ø35×110 mm; JD-R-05A, Jeung Do Bio & Plant Co., Ltd., Seoul, Korea).

[0209] At this time, the experimental environment for applying vibratory tactile stimulation consisted of a vibration signal input section, a vibration output section, and an output signal measurement section. Specifically, the signal generated from the function generator was input to the vibration output section at a voltage of up to 2.9 Vrms through an amplifier and converted into mechanical vibration, and the acceleration of the output vibration was precisely measured using an accelerometer and a data acquisition device (DAQ 200).

[0210] As a result of the measurement, the vibration acceleration range for each frequency applied in this experiment was confirmed to be 0.04 m / s to 0.4 m / s at 20 Hz, 0.1 m / s to 7.2 m / s at 40 Hz, and 0.1 m / s to 10.6 m / s at 80 Hz.

[0211] To apply the same administration and calibration stress to the normal and SCP control groups, they were calibrated for the same period in cylindrical acrylic mouse restraints included in the HVSS with the power cut off. (See Tables 1–3)

[0212]

[0213]

[0214]

[0215] 3. Observation Items

[0216] Body weight, passive avoidance test, water maze test, brain weight and gross morphological examination, changes in ACh content, AChE activity, and ChAT in the hippocampal region, as well as changes in the expression of memory-related genes—BDNF, PI3K, Akt, ERK1 and 2, CREB, and CaMK IV—the cerebral cortical antioxidant defense system, lipid peroxidation (MDA content), GSH content, SOD and CAT activity, histopathological changes in the brain hippocampal region, adrenal weight and gross morphological changes, changes in blood corticosterone content, and histopathological examination of the adrenal gland; the passive avoidance test and water maze test were performed 28 days after the start of vibratory tactile stimulation by HVSS and 24 hours after the final administration of SCP, respectively.

[0217] 4. Histomorphometric evaluation

[0218] Cerebrum: Average thickness of hippocampal CA1–CA3 (μm), normal hippocampal DG region, cleaved caspase-3 and c-Fos immune response, numerical changes in pyramidal neurons (cells / mm²)

[0219] Adrenal gland: Changes in thickness (μm) of the entire adrenal gland, medulla, and cortex, changes in thickness (μm) of the adrenal cortex glomerular layer, bundle layer, and reticular layer

[0220] - Experimental results

[0221] 1. Changes in weight

[0222] Figure 14 is a graph showing the changes in body weight of rats in the experimental examples of the present invention. Referring to Figure 14, no significant changes in body weight or weight gain over the 28-day administration period compared to the normal media control group were observed in any of the SCP treatment groups, respectively; similarly, no significant changes in body weight or weight gain compared to the SCP control group were observed throughout the entire experimental period in the 20, 40, and 80 Hz vibratory tactile stimulation experimental groups using HVSS. (See Table 4)

[0223]

[0224] During the 28-day administration period, the increase in body weight was 1.47% in the SCP control group compared to the normal media control group, and in the 20, 40, and 80 Hz vibratory tactile stimulation experimental groups using HVSS, changes of -0.85%, -0.73%, and 0.24%, respectively, compared to the SCP control group.

[0225] 2. Manual Avoidance Test

[0226] Figure 15 is a graph showing step-through latency times in a passive avoidance test of rats in an experimental example of the present invention. Referring to Figure 15, a significant (p<0.01) decrease in step-through latency time, i.e., the time spent in a bright room, was observed in the SCP control group compared to the normal media control group, but a significant (p<0.01) increase in step-through latency time was observed in the 40 and 80 Hz vibratory tactile stimulation experimental groups using HVSS compared to the SCP control group, to a similar degree. Meanwhile, no significant change in step-through latency time was observed in the 20 Hz vibratory tactile stimulation experimental group using HVSS compared to the SCP control group.

[0227] The retention latency period showed a change of -71.00% in the SCP control group compared to the normal media control group, but in the 20, 40, and 80 Hz vibratory tactile stimulation experimental groups using HVSS, changes of 2.34%, 82.19%, and 80.04%, respectively, compared to the SCP control group.

[0228] 3. Underwater maze test

[0229] Figure 16 is a graph showing the escape latency time in a water maze test of rats in an experimental example of the present invention. Referring to Figure 16, a significant (p<0.01) increase in escape latency time in finding the escape platform was observed in the SCP control group compared to the normal media control group, whereas a significant (p<0.01) decrease in escape latency time was observed in the 40 and 80 Hz vibratory tactile stimulation experimental groups using HVSS compared to the SCP control group, to a similar degree. Meanwhile, no significant change in escape latency time was observed in the 20 Hz vibratory tactile stimulation experimental group using HVSS compared to the SCP control group.

[0230] The escape latency period showed a change of 271.13% in the SCP control group compared to the normal media control group, but in the 20, 40, and 80 Hz vibratory tactile stimulation experimental groups using HVSS, changes of -0.83%, -48.26%, and -49.51%, respectively, compared to the SCP control group.

[0231] 4. Changes in brain weight

[0232] Figure 17 shows photographs illustrating the overall morphology of the rat brain in the experimental examples of the present invention. Referring to Figure 17, no significant macroscopic morphological changes in the brain or significant changes in absolute and relative brain weight relative to body weight were observed in the SCP control group compared to the normal media control group, except for significant changes in the olfactory bulb. Similarly, no significant macroscopic morphological changes in the brain or significant changes in absolute and relative brain weight were observed in the 20, 40, and 80 Hz vibratory tactile stimulation experimental groups using HVSS compared to the SCP control group. (See Table 5)

[0233]

[0234] The absolute brain weight showed a change of 0.41% in the SCP control group compared to the normal media control group, and in the 20, 40, and 80 Hz vibratory tactile stimulation experimental groups using HVSS, it showed changes of 0.12%, -0.29%, and 0.70%, respectively, compared to the SCP control group. The relative brain weight showed a change of 0.32% in the SCP control group compared to the normal media control group, and in the 20, 40, and 80 Hz vibratory tactile stimulation experimental groups using HVSS, it showed changes of 0.09%, -0.63%, and 0.83%, respectively, compared to the SCP control group.

[0235] 5. Changes in adrenal weight

[0236] Figure 18 shows photographs illustrating the overall morphology of the rat adrenal gland in the experimental examples of the present invention. Referring to Figure 18, no significant macroscopic morphological changes in the left adrenal gland or significant changes in absolute and relative body weight of the adrenal gland were observed in the SCP control group compared to the normal media control group; similarly, no significant macroscopic morphological changes in the adrenal gland or significant changes in absolute and relative body weight of the adrenal gland were observed in the 20, 40, and 80 Hz vibratory tactile stimulation experimental groups using HVSS compared to the SCP control group. (See Table 5)

[0237] The absolute weight of the adrenal gland showed a change of 7.14% in the SCP control group compared to the normal media control group, and in the 20, 40, and 80 Hz vibratory tactile stimulation experimental groups using HVSS, it showed changes of -6.67%, 0.00%, and -6.67%, respectively, compared to the SCP control group.

[0238] The relative weight of the adrenal gland showed a change of 5.65% in the SCP control group compared to the normal media control group, and in the 20, 40, and 80 Hz vibratory tactile stimulation experimental groups using HVSS, it showed changes of -6.64%, 1.93%, and -5.18%, respectively, compared to the SCP control group.

[0239] 6. Changes in blood corticosterone levels

[0240] Figure 19 is a graph showing serum corticosterone levels in rats in an experimental example of the present invention. Referring to Figure 19, no significant change in blood corticosterone content compared to the normal media control group was observed in the SCP control group, and no significant change in blood corticosterone content compared to the SCP control group was observed in the 20, 40, and 80 Hz vibratory tactile stimulation experimental groups using all HVSS.

[0241] The blood corticosterone content showed a change of 2.40% in the SCP control group compared to the normal media control group, and in the 20, 40, and 80 Hz vibratory tactile stimulation experimental groups using HVSS, it showed changes of -0.21%, 1.54%, and -0.48%, respectively, compared to the SCP control group.

[0242] 7. Changes in ACh content and AChE activity in hippocampal tissue

[0243] Figure 20 is a graph showing the hippocampal Ach content of a rat in an experimental example of the present invention. Figure 21 is a graph showing the hippocampal AchE content of a rat in an experimental example of the present invention.

[0244] Referring to Figures 20 and 21, in the SCP control group, a significant (p<0.01) decrease in ACh content and an increase in AChE activity were observed in the hippocampal tissue compared to the normal media control group, respectively; however, in the 40 and 80 Hz vibratory tactile stimulation experimental groups using HVSS, a significant (p<0.01) increase in ACh content and a decrease in AChE activity were observed in the hippocampal tissue compared to the SCP control group, respectively, to similar degrees.

[0245] Meanwhile, in the experimental group with 20Hz vibratory tactile stimulation using HVSS, no significant changes in ACh content and AChE activity in hippocampal tissue were observed compared to the SCP control group.

[0246] The ACh content in hippocampal tissue showed a change of -75.12% in the SCP control group compared to the normal media control group, but in the 20, 40, and 80 Hz vibratory tactile stimulation experimental groups using HVSS, it showed changes of 2.36%, 88.58%, and 88.98%, respectively, compared to the SCP control group.

[0247] AChE activity in hippocampal tissue showed a change of 141.02% in the SCP control group compared to the normal media control group, but in the 20, 40, and 80 Hz vibratory tactile stimulation experimental groups using HVSS, changes of -5.74%, -32.90%, and -33.26%, respectively, compared to the SCP control group.

[0248] 8. Cortical lipid peroxidation and changes in the endogenous antioxidant defense system

[0249] In the SCP control group, a significant (p<0.01) increase in MDA content and lipid peroxidation in the cerebral cortex tissue and a decrease in the activity of endogenous oxidant GSH, endogenous antioxidant enzyme SOD, and CAT were observed compared to the normal media control group, but in the 40 and 80 Hz vibratory tactile stimulation experimental groups using HVSS, a significant (p<0.01) decrease in MDA content in the cerebral cortex tissue and an increase in GSH content, SOD, and CAT activity were observed to similar degrees compared to the SCP control group.

[0250] Meanwhile, in the experimental group with 20Hz vibratory tactile stimulation using HVSS, no significant changes in MDA and GSH content and SOD and CAT activity within the cerebral cortex tissue were observed compared to the SCP control group. (See Table 6)

[0251]

[0252] The MDA content in the cerebral cortex tissue showed a change of 184.68% in the SCP control group compared to the normal media control group, but in the 20, 40, and 80 Hz vibratory tactile stimulation experimental groups using HVSS, it showed changes of -2.51%, -36.59%, and -35.09%, respectively, compared to the SCP control group.

[0253] The GSH content in the cerebral cortex tissue showed a change of -77.22% in the SCP control group compared to the normal media control group, but in the 20, 40, and 80 Hz vibratory tactile stimulation experimental groups using HVSS, it showed changes of 3.83%, 112.93%, and 116.87%, respectively, compared to the SCP control group.

[0254] CAT activity in the cerebral cortex tissue showed a change of -78.62% in the SCP control group compared to the normal media control group, but in the 20, 40, and 80 Hz vibratory tactile stimulation experimental groups using HVSS, changes of 1.98%, 103.92%, and 104.52%, respectively, compared to the SCP control group.

[0255] SOD activity in the cerebral cortex tissue showed a change of -82.61% in the SCP control group compared to the normal media control group, but in the 20, 40, and 80 Hz vibratory tactile stimulation experimental groups using HVSS, changes of 2.46%, 145.43%, and 142.04%, respectively, compared to the SCP control group.

[0256] 9. Changes in mRNA expression of ChAT and memory-related genes in hippocampal tissue—BDNF, PI3K, Akt, ERK1 and 2, CREB, and CaMK IV

[0257] In the SCP control group, a significant (p<0.01) decrease in the expression of ChAT, BDNF, PI3K, Akt, ERK1 and 2, CREB, and CaMK IV mRNA in hippocampal tissue was observed compared to the normal media control group, but in the 40 and 80 Hz vibratory tactile stimulation experimental groups using HVSS, a significant (p<0.01) increase in the expression of ChAT and memory-related genes—BDNF, PI3K, Akt, ERK1 and 2, CREB, and CaMK IV mRNA—in hippocampal tissue was observed to similar degrees compared to the SCP control group.

[0258] Meanwhile, in the experimental group with 20Hz vibratory tactile stimulation using HVSS, no significant changes in the expression of ChAT, BDNF, PI3K, Akt, ERK1 and 2, CREB, and CaMK IV mRNA within hippocampal tissue were observed compared to the SCP control group. (See Table 7)

[0259]

[0260] ChAT mRNA expression in hippocampal tissue showed a change of -68.73% in the SCP control group compared to the normal media control group, but in the 20, 40, and 80 Hz vibratory tactile stimulation experimental groups using HVSS, changes of 1.59%, 83.44%, and 85.03%, respectively, compared to the SCP control group.

[0261] BDNF mRNA expression in hippocampal tissue showed a change of -68.64% in the SCP control group compared to the normal media control group, but in the 20, 40, and 80 Hz vibratory tactile stimulation experimental groups using HVSS, changes of 1.92%, 57.19%, and 56.87%, respectively, compared to the SCP control group.

[0262] PI3K mRNA expression in hippocampal tissue showed a change of -70.52% in the SCP control group compared to the normal media control group, but in the 20, 40, and 80 Hz vibratory tactile stimulation experimental groups using HVSS, changes of 6.71%, 74.83%, and 75.84%, respectively, compared to the SCP control group.

[0263] Akt mRNA expression in hippocampal tissue showed a change of -70.43% in the SCP control group compared to the normal media control group, but in the 20, 40, and 80 Hz vibratory tactile stimulation experimental groups using HVSS, changes of 6.98%, 65.12%, and 63.79%, respectively, compared to the SCP control group.

[0264] ERK1 mRNA expression in hippocampal tissue showed a change of -75.27% in the SCP control group compared to the normal media control group, but in the 20, 40, and 80 Hz vibratory tactile stimulation experimental groups using HVSS, it showed changes of 3.59%, 73.71%, and 74.90%, respectively, compared to the SCP control group.

[0265] ERK2 mRNA expression in hippocampal tissue showed a change of -80.46% in the SCP control group compared to the normal media control group, but in the 20, 40, and 80 Hz vibratory tactile stimulation experimental groups using HVSS, changes of 3.41%, 105.85%, and 105.37%, respectively, compared to the SCP control group.

[0266] CREB mRNA expression in hippocampal tissue showed a change of -70.32% in the SCP control group compared to the normal media control group, but in the 20, 40, and 80 Hz vibratory tactile stimulation experimental groups using HVSS, it showed changes of 7.72%, 75.17%, and 74.50%, respectively, compared to the SCP control group.

[0267] CaMK IV mRNA expression in hippocampal tissue showed a change of -73.37% in the SCP control group compared to the normal media control group, but in the 20, 40, and 80 Hz vibratory tactile stimulation experimental groups using HVSS, changes of 1.82%, 84.31%, and 86.13%, respectively, compared to the SCP control group.

[0268] 10. Histopathological changes

[0269] 10.1 Histopathological changes in the hippocampus

[0270] Fig. 22 is a representative histopathological image of the mouse brain-hippocampus in an experimental example of the present invention. Fig. 23 is a representative image of caspase-3 immunolabeled pyramidal cells in the DG region of the mouse brain-hippocampus in an experimental example of the present invention. Fig. 24 is a representative image of c-Fos immunopositive pyramidal cells in the DG region of the mouse brain-hippocampus in an experimental example of the present invention.

[0271] Referring to Figures 22 to 24, in the SCP control group, a significant (p<0.01) decrease in hippocampal CA1–CA2 thickness, normal DG region, and the number of c-Fos immune-responsive pyramidal neurons were observed compared to the normal media control group, along with an increase in the number of cleaved caspase-3 immune-responsive apoptosis [Kim et al., 2016; Xu et al., 2016] pyramidal neurons in the hippocampal DG region, respectively. However, in the 40 and 80 Hz vibratory tactile stimulation experimental groups using HVSS, a significant (p<0.01) increase in hippocampal CA1–CA2 thickness, normal DG region, and the number of c-Fos immune-responsive pyramidal neurons were observed compared to the SCP control group, along with a decrease in the number of cleaved caspase-3 immune-responsive pyramidal neurons in the hippocampal DG region, respectively, to similar degrees.

[0272] Meanwhile, in the experimental group with 20Hz vibratory tactile stimulation using HVSS, no significant changes in hippocampal CA1–CA2 thickness, normal DG region, or the number of pyramidal neurons in c-Fos and cleaved caspase-3 immune responses were observed compared to the SCP control group. (See Table 8)

[0273]

[0274] The thickness of the cerebral hippocampus CA1 to CA2 showed a change of -20.17% in the SCP control group compared to the normal media control group, but in the 20, 40, and 80 Hz vibratory tactile stimulation experimental groups using HVSS, it showed changes of 1.28%, 15.14%, and 14.29%, respectively, compared to the SCP control group.

[0275] The number of normal pyramidal neurons in the DG region of the cerebral hippocampus showed a change of -34.65% in the SCP control group compared to the normal media control group, but in the 20, 40, and 80 Hz vibratory tactile stimulation experimental groups using HVSS, the numbers showed changes of 1.34%, 34.46%, and 32.53%, respectively, compared to the SCP control group.

[0276] The number of apoptosis pyramidal neurons in the cleaved caspase-3 immune response in the DG region of the cerebral hippocampus showed a change of 404.00% in the SCP control group compared to the normal media control group, but in the 20, 40, and 80 Hz vibratory tactile stimulation experimental groups using HVSS, changes of -3.97%, -52.78%, and -53.17%, respectively, compared to the SCP control group.

[0277] The number of pyramidal neurons with c-Fos immune response activation in the cerebral hippocampal DG region showed a change of -88.55% in the SCP control group compared to the normal media control group, but in the 20, 40, and 80 Hz vibratory tactile stimulation experimental groups using HVSS, changes of 3.33%, 446.67%, and 440.00%, respectively, compared to the SCP control group.

[0278] 10.2. Histopathological changes of the adrenal gland

[0279] Figure 25 shows representative histopathological images of the adrenal gland of a rat in an experimental example of the present invention. Referring to Figure 25, no significant changes in the thickness of the entire adrenal gland, medulla, cortex, adrenal cortex glomerular layer, bundle layer, and reticular layer were observed in the SCP control group compared to the normal media control group, and no significant histopathological changes in the adrenal gland were observed in the 20, 40, and 80 Hz vibratory tactile stimulation experimental groups using HVSS compared to the SCP control group. (See Table 9)

[0280]

[0281] The total thickness of the adrenal gland showed a change of 1.51% in the SCP control group compared to the normal media control group, but in the 20, 40, and 80 Hz vibratory tactile stimulation experimental groups using HVSS, changes of -1.48%, 0.03%, and -1.31%, respectively, compared to the SCP control group.

[0282] The thickness of the adrenal medulla showed a change of 0.58% in the SCP control group compared to the normal media control group, but in the 20, 40, and 80 Hz vibratory tactile stimulation experimental groups using HVSS, it showed changes of -3.30%, -1.51%, and -3.51%, respectively, compared to the SCP control group.

[0283] The thickness of the adrenal cortex showed a change of 1.93% in the SCP control group compared to the normal media control group, but in the 20, 40, and 80 Hz vibratory tactile stimulation experimental groups using HVSS, it showed changes of -0.67%, 0.72%, and -0.33%, respectively, compared to the SCP control group.

[0284] The thickness of the adrenal cortex glomerular layer showed a change of 0.61% in the SCP control group compared to the normal media control group, but in the 20, 40, and 80 Hz vibratory tactile stimulation experimental groups using HVSS, it showed changes of 1.35%, 1.59%, and 1.61%, respectively, compared to the SCP control group.

[0285] The thickness of the adrenal cortex bundle layer showed a change of 2.74% in the SCP control group compared to the normal media control group, but in the 20, 40, and 80 Hz vibratory tactile stimulation experimental groups using HVSS, changes of -1.29%, 0.56%, and -0.67%, respectively, compared to the SCP control group.

[0286] The thickness of the adrenal cortex reticular layer showed a change of -0.67% in the SCP control group compared to the normal media control group, but in the 20, 40, and 80 Hz vibratory tactile stimulation experimental groups using HVSS, it showed changes of -0.13%, 0.29%, and -1.30%, respectively, compared to the SCP control group.

[0287] Under the experimental conditions described above, vibratory tactile stimulation at 40 and 80 Hz by HVSS was judged to be reliable evidence showing relatively superior memory improvement effects in a C57BL / 6 mouse model of SCP-induced memory impairment through the regulation of memory-related gene expression—BDNF, PI3K, Akt, ERK1 and 2, CREB, and CaMK IV—along with neuroprotective effects through cholinergic neuroactivity and antioxidant effects to similar degrees, without accompanying severe stress and related side effects. Therefore, HVSS, which generates appropriate vibratory tactile stimulation, particularly at 40 Hz, is expected to have a very high potential for development as an effective medical device for improving cognitive function for various memory impairments, including dementia, through further detailed mechanistic studies, various animal experiments, and appropriate human clinical trials.

[0288] Based on the experimental examples examined above, it was confirmed that there is an effect of improving memory and treating cognitive impairment at about 20 to 100 Hz, particularly at 40 Hz or 80 Hz, and in particular, it was confirmed that the neural stimulation control device (1) of the present invention can be used for medicinal purposes. Although the above experimental examples relate to animal experiments, it is expected that by applying the neural stimulation control device (1) of the present invention to humans, for example, by using it in a manner that stimulates for 10 minutes once a day for 28 days, brain disorders or cognitive impairments can be improved, prevented, or treated.

[0289] FIGS. 26 to 30 relate to experimental examples of cell experiments of the present invention, and include a diagram of the cell experiment configuration for acoustic vibration, a conceptual diagram schematically explaining the overall contents of the acoustic vibration cell experiment, and graphs showing the experimental results.

[0290] Referring to Figures 26 to 30, the mechanism of action (MoA) can be confirmed through cell experiments, and cell experiments were conducted to confirm the molecular biological mechanism of how acoustic vibrations including 40 Hz affect brain cells.

[0291] As a result, the inhibitory effect on autophagy activation (increase in Atg5, LC3B) and tau hyperphosphorylation was confirmed in human-derived neurons (SH-SY5Y), and a significant decrease in neuroinflammatory cytokines (IL-1β, TNF-α, IL-6) was confirmed in BV-2 mouse microglia.

[0292] This demonstrates that the vibrational stimulation of the present invention can directly inhibit amyloid beta and tau pathologies at the cellular level.

[0293] [Example 2]

[0294] - Clinical trial design and subjects

[0295] FIG. 31 is a schematic diagram showing the characteristics and assignment status of subjects in a clinical trial according to the present invention. FIG. 32 is a table showing a summary of adverse events (AEs) observed during the clinical trial according to the present invention.

[0296] Referring to FIGS. 31 and 32, this clinical trial was conducted to collect information on the efficacy and safety of reducing symptoms of memory and cognitive decline in early-stage Alzheimer's disease patients through a comparison of the neural stimulation control device (1) according to the present invention and a Sham device, and to establish the design and basis for subsequent clinical trials.

[0297] The study was designed as a single-center, randomized, double-blind, parallel-design, sham device-controlled clinical trial for medical device exploration. The study was conducted from March 6, 2024, to October 2, 2025, and included a total of 30 patients with early-stage Alzheimer's disease (considering a 20% dropout rate). These patients were randomly assigned to an active group (20 patients) and a sham group (10 patients) for 24 weeks.

[0298] - Selection and Exclusion Criteria

[0299] Selection Criteria: Subjects satisfying all of the following criteria were selected.

[0300] 1. Men and women aged 55 to 80.

[0301] 2. Persons in whom the subject or guardian complains of the subject's memory decline.

[0302] 3. Individuals with mild cognitive impairment or mild dementia that meets the criteria for Alzheimer's disease (AD) as defined by stages 3-4 according to the National Institute on Aging and Alzheimer's Association Research Framework (NIA-AA) at the time of screening.

[0303] 4. Those diagnosed with early-stage Alzheimer's disease on the SNSB performed during screening (Visit 1).

[0304] 5. Those with a K-MMSE-2 score of 20 to 28.

[0305] 6. A person whose Clinical Dementia Rating (CDR) score is 0.5 to 1 point, wherein the score for the memory item is 0.5 or 1 point.

[0306] 7. Patients who are able to move even with the use of walking aids, possess sufficient vision, hearing, language ability, motor function, and comprehension to follow examination procedures, and have voluntarily given written consent.

[0307] Exclusion Criteria: Persons falling under any of the following items were excluded.

[0308] 1. Associates with neurological diseases such as cerebrovascular disease and Parkinson's disease.

[0309] 2. Persons with severe hearing impairment.

[0310] 3. Persons with a history of treatment for mental illness within the last 3 months.

[0311] 4. Participants in other clinical trials within the last 3 months.

[0312] 5. Persons who have suffered a stroke within the last 24 months.

[0313] 6. People taking anticoagulants.

[0314] 7. Persons with a history of seizures / epilepsy within the last 24 months.

[0315] 8. Carriers of a malignant tumor within the last 5 years.

[0316] 9. Users of wearable electronic medical devices, such as electrocardiographs.

[0317] 10. Pregnant women, breastfeeding women, or women of childbearing age who do not consent to the use of medically acceptable contraception.

[0318] 11. Patients with muscle injury and fractures.

[0319] 12. Patients with chronic skin diseases.

[0320] 13. Persons with a history of brain stimulation therapy.

[0321] 14. Persons with a history of intracranial implants.

[0322] 15. An uneducated and illiterate person.

[0323] 16. Individuals whose dosage of Alzheimer's disease-related medication has not been stable for at least 3 months prior to screening.

[0324] 17. Other persons deemed unsuitable by the principal investigator.

[0325] - Clinical Trial Methods (Usage and Dosage)

[0326] The medical devices used in this clinical trial (devices for the test group and the control group) were worn so as to be in close contact with the subjects' heads, specifically the frontal and temporal lobes. The application period and dosage involved applying stimulation once a day for 30 minutes for a total of 24 weeks, and the sessions were conducted during the morning or afternoon hours when the subjects felt comfortable.

[0327] The specific visit schedule and execution procedures for the entire clinical trial were structured as follows.

[0328] Visit 1 (Screening, D-28~0): Written consent, medical history review, vital signs / anthropometrics, pregnancy test, clinical pathology tests, SNSB, CDR-SB, K-MMSE-2 evaluation, determination of inclusion / exclusion criteria and confirmation of concomitant medications.

[0329] Visit 2 (Baseline, D0): Vital signs / anthropometrics, pregnancy test, ADAS-K-cog-13, brain vMRI, brain SPECT, quantitative electroencephalogram (QEEG), randomization, device administration, patient log distribution, and concomitant medication verification.

[0330] Visit 3 (Week 12 ± 7): Vital signs / anthropometrics, ADAS-K-cog-13, QEEG, distribution / collection of patient logs, evaluation of device compliance / concomitant medications / adverse events.

[0331] Visit 4 (Week 24 ± 7): Vital signs / anthropometric measurements, pregnancy test, clinical pathology tests, CDR-SB, ADAS-K-cog-13, vMRI, SPECT, QEEG, retrieval of patient log, retrieval of equipment, and overall safety evaluation.

[0332] - Evaluation of the validity of observation items and evaluation methods

[0333] As the primary efficacy endpoint, the change in the Clinical Dementia Rating Scale (CDR-SB) from baseline to 24 weeks was analyzed. As the secondary efficacy endpoint, the change in the Alzheimer's Disease Rating Scale (ADAS-K-cog-13) score from baseline to 12 and 24 weeks was measured.

[0334] In addition, vMRI analysis for changes in brain structural volume at 24 weeks relative to baseline, SPECT analysis for changes in local cerebral blood flow metabolism, and QEEG analysis for visualization of spectral characteristics of each frequency band (Delta, Theta, Alpha, Beta, Gamma) and network coherence (Coherence, Functional connectivity) were included.

[0335] Safety evaluation assessed vital signs (blood pressure, pulse, body temperature), anthropometric measurements, clinical pathology tests, adverse events (TEAEs), and concomitant drug monitoring.

[0336] - Test / Visit Schedule

[0337]

[0338] - Statistical analysis methods

[0339] The efficacy evaluation was conducted on subjects who complied with the protocol (FAS), and the safety evaluation was conducted on the safety analysis set. Unless otherwise specified, statistical analysis was performed using two-sided tests at a 5% significance level.

[0340] 1. Analysis of Validity Evaluation Variables

[0341] 1) Primary efficacy endpoint

[0342] ① Differences between groups regarding the change in CDR-SB from baseline to 24 weeks

[0343] 2) Secondary efficacy evaluation variable

[0344] ① Differences between groups regarding changes in ADAS-K-cog-13 at 12 and 24 weeks relative to baseline. The changes in ADAS-K-cog-13 at 12 and 24 weeks relative to baseline were analyzed using an independent t-test or Mann-Whitney U test after determining normality.

[0345] ② Differences between groups regarding changes in vMRI at 24 weeks relative to baseline. The changes in vMRI after 24 weeks relative to baseline were analyzed using an independent t-test or Mann-Whitney U test after determining normality.

[0346] ③ Differences between groups regarding changes in SPECT at 24 weeks relative to baseline. The changes in SPECT values ​​after 24 weeks relative to baseline were analyzed using an independent t-test or Mann-Whitney U test after determining normality.

[0347] ④ Analysis of QEEG changes from baseline at 24 weeks: Resting-state EEGs were acquired before and after the use of the instrument, and the spectral characteristics of each frequency band (delta, theta, alpha, beta, gamma) were quantified through QEEG analysis. In addition, the coherence and network structure of each channel pair were visualized and analyzed using a coherence matrix and a functional connectivity map.

[0348] 2. Analysis of Safety Evaluation Variables

[0349] 1) Adverse reactions

[0350] The summary and analysis of adverse events focused on Treatment-Emergent Adverse Events (TEAEs) that occurred after medical device treatment. The frequency and percentage of adverse events (TEAEs) and serious adverse events (SAEs) occurring after treatment with the investigational medical device were presented, and differences between treatment groups were analyzed using Pearson's chi-square test. Adverse events were coded according to SOC and PT using MedDRA version 24.0, and the number of subjects, incidence rates, and number of occurrences of each coded adverse event were presented by treatment group.

[0351] 2) Concomitant drugs

[0352] The frequency and percentage regarding the presence or absence of concomitant drugs were presented, and differences between treatment groups were analyzed using Pearson's chi-square test. Concomitant drugs were classified into the Anatomical Main Group and Therapeutic / pharmacological subgroups according to the WHOATC Index, and the frequency and percentage were presented for each treatment group.

[0353] 3) Vital signs and anthropometric measurements

[0354] Descriptive statistics for vital signs and anthropometric measurements (weight) were presented at each time point. Within-group changes were assessed using the Paired t-test, and between-group comparisons were performed using the Independent Sample t-test. However, in cases where normality was not satisfied, within-group changes were assessed using the Wilcoxon Signed Rank Test, and between-group comparisons were performed using Mann Whitney's U test.

[0355] 4) Clinical pathology tests

[0356] The number and percentage of subjects assessed as clinically significant abnormal were presented at baseline and at 24 weeks (Visit 4). Changes before and after treatment were compared using the McNemar test, and comparisons between groups were made using Pearson's chi-square test. Descriptive statistics for continuous variables in clinical pathology test results were presented at baseline and at 24 weeks. Within-group changes were confirmed using the Paired t-test, and comparisons between groups were made using the Independent Two-Sample t-test. However, in cases where normality was not satisfied, within-group changes were confirmed using the Wilcoxon Signed Rank Test, and comparisons between groups were made using the Mann-Whitney's U test.

[0357] - Compliance and safety results

[0358] The efficacy evaluation assessed the subjects' adherence to the device during the clinical trial period. The results showed that even in a daily home usage environment, the test group (Active group) achieved approximately 97–98% adherence, while the control group (Sham group) achieved approximately 98%. This demonstrates that the device of the present invention is highly suitable for long-term daily application by patients with early-stage Alzheimer's disease and offers excellent usability. Furthermore, an evaluation of safety related to device use revealed that not a single serious adverse event occurred.

[0359] Specifically, at week 12 of the clinical trial, both the test group and the control group showed an adverse event rate of 0%, demonstrating excellent initial tolerability. At week 24, only mild adverse events unrelated to the device treatment were reported, with only 1 case (low back pain, 5.3%) in the test group and 2 cases (right shoulder pain and dizziness, 22.2%) in the control group.

[0360] Through this, it has been confirmed that the neural stimulation control device of the present invention is very safe for long-term use of 24 weeks or more without concerns about side effects that can be caused by existing non-invasive brain stimulation devices.

[0361] - Exploratory Indicators: Plasma Biomarker Evaluation Items

[0362] In addition, for efficacy evaluation, plasma samples from subjects are collected as exploratory biomarkers to evaluate key pathological proteins and neurological damage indicators of Alzheimer's disease.

[0363] Specific plasma biomarkers include changes in levels of hyperphosphorylated tau protein pTau-217, amyloid beta ratio (Aβ42 / 40 ratio), glial fibrillary acidic protein (GFAP), and neurofiber microfilament chain (NfL).

[0364] Through the measurement of the above plasma biomarkers, the effects of transcranial acoustic vibration (tVAS) stimulation according to the present invention on the preservation of brain structure and function as well as the progression of molecular biological pathology are comprehensively analyzed, and the related evaluation results are to be finally obtained after the completion of the 24-week treatment period and the extension study (OLE).

[0365] - 24-Week Open Label Extension Study (OLE) Information

[0366] The overall study design of this clinical trial consists of an initial 24-week double-blind Treatment Phase, followed by a 24-week Open-label Extension Phase (OLE) to track the long-term safety and efficacy of patients after the end of this period.

[0367] That is, the active device of the present invention is applied in the same way during an extended study period (24 weeks) to all subjects who were assigned to the test group or control group during a double-blind period of 24 weeks, and the sustained effect of alleviating brain function decline due to long-term stimulation and the long-term safety profile are additionally collected and evaluated.

[0368] [Example 3]

[0369] - Analysis of the effect of mitigating structural brain volume (whole brain, hippocampus, amygdala) atrophy via brain MRI

[0370] FIGS. 33 to 35 are graphs showing the effect of alleviating structural volume atrophy of the total brain volume, hippocampus, and amygdala through brain MRI analysis according to the present invention.

[0371] Referring to FIGS. 33 to 35, in this embodiment, according to the clinical trial protocol of Example 2, changes in total brain volume, hippocampus, and amygdala volumes after 24 weeks from before (baseline) application of transcranial oscillatory stimulation (tVAS) in early Alzheimer's disease patients were analyzed using brain vMRI.

[0372] 3-1. Analysis of Changes in Total Brain Volume

[0373] In the brain MRI analysis, the average change in total brain volume from baseline after 24 weeks was -3.05 ± 5.48 for the test group (Active group) and -8.51 ± 9.31 for the control group (Sham group). When comparing the average changes between the two groups, the decrease in brain volume in the test group was approximately 36% of that of the control group, showing a trend of about 64% more gradual decline compared to the control group. These results can be interpreted as a trend indicating the potential for transcranial acoustic vibration stimulation (tVAS) to significantly alleviate the progression of total brain atrophy.

[0374] 3-2. Deep Brain Structure: Analysis of Hippocampus Volume Changes

[0375] We compared the change in hippocampal volume from baseline after 24 weeks, which plays an important role in memory formation and learning function and is a representative region where early atrophy occurs in degenerative cognitive diseases.

[0376] Analysis results showed -0.13 ± 0.04 for the test group and -0.19 ± 0.07 for the control group. When comparing the average change, the decrease in hippocampal volume in the test group was found to be about 68% of that of the control group, showing a trend of atrophy progression that was about 32% more gradual. This indicates that the neural stimulation control device (1) of the present invention has the potential to alleviate the progression of atrophy in the hippocampus, which is a core memory-regulating region.

[0377] 3-3. Structure of the Limbic System: Analysis of Amygdala Volume Changes

[0378] We compared the change in amygdala volume after 24 weeks, a limbic system structure closely related to emotion regulation, memory processing, and emotional response, in which structural changes are reported in neurodegenerative diseases.

[0379] The analysis results showed -0.05 ± 0.04 for the test group and -0.22 ± 0.06 for the control group. When comparing the average changes, the decrease in amygdala volume in the test group was only about 23% of that of the control group, showing a trend of atrophy progression that was approximately 77% more gradual than that of the control group. This demonstrates the potential for transcranial acoustic vibration stimulation (tVAS) to strongly prevent the progression of pathological atrophy of limbic system structures.

[0380] When the brain MRI analysis results are combined, it is proven that the transcranial acoustic vibration energy applied by the neural stimulation control device (1) of the present invention not only inhibits the progression of macroscopic total brain atrophy by 64% more slowly, but also has a significant effect in preventing the reduction of anatomical volume of the hippocampus and amygdala located deep in the brain by 32% and 77% more slowly, respectively.

[0381] This supports the clinical confirmation of a key mechanism that physically delays the atrophy of degenerative brain structures by inducing mechanical resonance in deep brain tissues through the skull with mechanical wave energy of a specific critical acceleration (0.25 to 0.90 m / s²).

[0382] [Example 4]

[0383] - Analysis of local cerebral blood flow changes via brain SPECT

[0384] Figure 36 is a graph showing the local cerebral blood flow protection effect of major brain regions (PCC Precuneus, Lateral Parietal, Lateral Temporal, and Medial Temporal) through brain SPECT according to the present invention.

[0385] Referring to FIG. 36, in this Example 4, according to the clinical trial protocol of Example 2, changes in local cerebral blood flow metabolism were analyzed 24 weeks after the application of transcranial acoustic vibration stimulation (tVAS) to early Alzheimer's disease patients using brain SPECT (single-photon emission computed tomography) compared to baseline.

[0386] 1. Analysis of average changes in cerebral blood flow by major brain regions. When comparing changes in local cerebral blood flow after 24 weeks from baseline in brain SPECT analysis, the test group (Active group) showed a significantly reduced decrease in cerebral blood flow compared to the control group (Sham group), and the specific figures are as follows.

[0387] PCC-Precuneus area: -0.94 ± 0.68 for the test group and -1.62 ± 1.12 for the control group, confirming that the decrease in blood flow in the test group was approximately 58% of that of the control group.

[0388] Lateral Parietal region: The test group was -0.66 ± 0.66 and the control group was -1.14 ± 1.09, showing a reduction of approximately 58% compared to the control group.

[0389] Lateral Temporal region: The test group was -0.44 ± 0.74 and the control group was -1.99 ± 1.19, showing a decrease of approximately 22% compared to the control group.

[0390] Medial Temporal region: The test group was -0.98 ± 0.95 and the control group was -2.65 ± 1.56, showing a decrease of approximately 37% compared to the control group.

[0391] Overall, in all analyzed target brain regions, the decrease in cerebral blood flow in the test group (Active group) was only about 22–58% of that in the control group (Sham group), so a consistent trend was observed in which the decrease in cerebral blood flow progressed relatively much more gradually.

[0392] The analyzed regions correspond to the Default Mode Network (DMN) and the Medial Temporal Memory Circuit, which are representative brain networks in which early reductions in metabolism and blood flow are prominent in patients with Alzheimer's disease.

[0393] In particular, the PCC-Precuneus region is a key hub area closely associated with memory networks, and the medial temporal lobe region is a key structure related to the hippocampus and memory formation.

[0394] Therefore, these cerebral blood flow defense data are interpreted as a strong exploratory trend suggesting that transcranial acoustic vibration stimulation (tVAS) according to the present invention can structurally and functionally significantly alleviate the progression of reduced cerebral blood flow in the most vulnerable brain network regions in Alzheimer's disease.

[0395] [Example 5]

[0396] - Analysis of changes in Clinical Decision Rating Scales (CDR-SB and ADAS-K-Cog 13)

[0397] FIG. 37 is a graph showing the change from baseline of the Clinical Dementia Rating Scale (CDR-SB) among the clinical cognitive function evaluation scales according to the present invention. FIG. 38 is a graph showing the change from baseline of the Alzheimer's Disease Rating Scale (ADAS-K-Cog 13) among the clinical cognitive function evaluation scales according to the present invention.

[0398] Referring to FIGS. 37 and 38, in this Example 5, according to the clinical trial protocol of Example 2, changes in CDR-SB (Clinical Dementia Rating Scale) and ADAS-K-Cog 13 (Alzheimer's Disease Rating Scale) scores were analyzed to determine changes in actual clinical cognitive function and ability to perform daily activities after 24 weeks compared to before the application of transcranial acoustic vibration stimulation (tVAS) (baseline) in patients with early-stage Alzheimer's disease.

[0399] 5-1. Primary Validity Evaluation: Analysis of CDR-SB Score Changes

[0400] The CDR-SB is a representative clinical scale that assesses the degree of dementia progression by reflecting overall cognitive and functional changes, such as memory, judgment, social function, and the ability to perform daily activities.

[0401] The evaluation results showed that the average change from baseline after 24 weeks was 0.29 ± 0.18 in the test group (Active group) and 0.62 ± 0.30 in the control group (Sham group). Overall, due to the nature of degenerative diseases, an increase in scores (worsening) was observed in both groups; however, the rate of cognitive decline in the test group was only about 47% of that of the control group. In other words, it showed a tendency for cognitive decline to progress approximately 53% more gradually compared to the control group.

[0402] 5-2. Secondary Validity Assessment: Analysis of ADAS-K-Cog 13 Score Changes

[0403] ADAS-K-Cog 13 is a core assessment tool for Alzheimer's disease clinical trials that comprehensively evaluates various cognitive domains, including memory, language ability, and executive function. The results of the analysis of score changes from baseline at 12 and 24 weeks are as follows.

[0404] Changes in cognitive function after 12 weeks: The average change from baseline after 12 weeks was 0.26 ± 0.94 for the test group and 1.33 ± 1.57 for the control group. The increase in scores in the test group was only about 20% of that of the control group, showing a tendency for the progression of cognitive deterioration to be alleviated by about 80% in just 12 weeks.

[0405] Changes in cognitive function and statistical significance after 24 weeks: After 24 weeks, the average change was -0.14 ± 0.96 for the test group and 4.18 ± 1.61 for the control group. In the test group, there was little to no change in scores or even a slight improvement (-0.14), whereas in the control group, a significant increase in scores (4.18) was observed.

[0406] This clearly shows that the progression of cognitive decline in the test group was mostly suppressed. In particular, when comparing the average change at the 24-week mark, the test group achieved a statistically significant difference (p=0.044) compared to the control group, thereby legally and clinically proving the definite cognitive improvement effect of the present invention.

[0407] Synthesizing the evaluation results of CDR-SB and ADAS-K-Cog 13, it is proven that transcranial acoustic vibration stimulation (tVAS) with specific parameters (36 Hz to 44 Hz, 0.25 m / s to 0.90 m / s) according to the present invention significantly inhibits the progression of cognitive decline in patients with early-stage Alzheimer's disease.

[0408] The macroscopic physical effects identified in the examples—namely, protection against anatomical atrophy of deep brain tissue (MRI) and inhibition of local cerebral blood flow metabolic reduction (SPECT)—are interpreted as strong efficacy data confirming that they were perfectly directly linked to a visible therapeutic prognosis of delaying the deterioration of clinical cognitive function in actual patients (80% remission and p<0.05).

[0409] [Example 6]

[0410] - Analysis of cortical network realignment and connectivity changes via Quantitative Electroencephalography (QEEG)

[0411] FIGS. 39 to 41 show the results of quantitative electroencephalography (QEEG) analysis according to the present invention, where FIG. 39 shows the change in spectrum characteristics (Topoplot) by frequency band, FIG. 40 shows the change in coherence matrix, and FIG. 41 shows the result of restructuring the functional connectivity map structure.

[0412] Referring to FIGS. 39 to 41, in Example 6, quantitative electroencephalograms (QEEG) at baseline, 12 weeks, and 24 weeks were analyzed to confirm time-series changes in the electrophysiological cortical network following the application of transcranial oscillatory stimulation (tVAS) to patients with early-stage Alzheimer's disease, in accordance with the clinical trial protocol of Example 2.

[0413] 6-1. Changes in Spectral Characteristics by Frequency Band (PSD - Topoplot Analysis)

[0414] Patients with early-stage Alzheimer's disease typically exhibit a characteristic 'EEG slowing' pattern, characterized by an increase in low-frequency bands (Delta, Theta) and a decrease in high-frequency bands (Alpha, Beta, Gamma), which reflect the decline in brain network function.

[0415] Analysis of changes in EEG topography after 24 weeks of stimulation in the test group (Active group) revealed that the Delta and Theta bands decreased, indicating a reduction in the pathological EEG slowing pattern associated with disease progression.

[0416] Conversely, the Alpha band expanded centered on the frontal and central regions, while the Beta and Gamma bands also increased. This suggests the potential for the recovery of cortical network activity, increased cognitive processing efficiency, and improvements in brain network synchronization and information processing integration functions.

[0417] 6-2. Changes in Time-Series Brain Network Cohesion (Coherence Matrix Analysis)

[0418] Analysis of changes in cohesion between brain channel pairs at 12 and 24 weeks after stimulus application revealed a distinct two-stage adaptation and realignment process.

[0419] Phase 1 (baseline to 12 weeks): A temporary increase in cohesion was observed across the entire brain network, including the Delta band. This is interpreted as the initial adaptation process of the brain network to external stimuli and as a phenomenon of increased synchronization where neuroplasticity is activated.

[0420] Phase 2 (Weeks 12–Week 24): At Week 24, the cohesion of the Delta band, which had increased at Week 12, decreased again, indicating that the patient's characteristic excessive and inefficient slow-wave synchronization had eased. On the other hand, the Alpha band, associated with the formation of a resting-state network, and the Gamma band, associated with high-dimensional cognitive processing, showed a pattern of structural reorganization in which the cohesive regions became more organized and selective connections were strengthened around specific core networks.

[0421] 6-3. Reorganization of Functional Network Structure (Functional connectivity map analysis)

[0422] Analysis of functional connectivity patterns between brain regions revealed that the overall excessive connectivity pattern (inefficient synchronization) observed at baseline decreased significantly over time.

[0423] Specifically, in the Delta band, lines indicating strong connections decreased, alleviating pathologically increased slow-wave activity. Conversely, in the Alpha band, strong connections between the frontal and occipital lobes increased at week 12, after which they were reorganized into a clear and organized network centered on necessary information exchange by week 24. The Gamma band also showed a tendency for strong functional connections to re-establish around specific core regions following the dismantling of existing inefficient networks.

[0424] Synthesizing the results of the QEEG analysis, the transcranial acoustic vibration stimulation (tVAS) according to the present invention has a significant effect of activating neuroplasticity in the early stages of stimulation (12 weeks), alleviating abnormal slow-wave (Delta / Theta) activity in the later stages of stimulation (24 weeks), and simultaneously realigning the brain's connectivity structure around the high-frequency (Alpha / Gamma) core network.

[0425] This is electrophysiological evidence proving that tVAS reduces unnecessary or inefficient connections within brain networks and reorganizes them into an efficient structure, which is strongly mechanistically associated with the improvement results of cognitive indicators (ADAS-Cog, etc.) confirmed in the previous examples.

Claims

1. A vibration device that is worn on the head of a subject with cognitive impairment or degenerative neurological disease to apply transcranial vibroacoustic stimulation (tVAS) for improving cognitive function; comprising The above vibration device is a neural stimulation control device controlled by a critical acceleration that applies physical transcranial acoustic vibration having a frequency selected or adjusted for each subject within a range of 20 Hz to 120 Hz to the head of the subject, and penetrates vibration energy, which is a mechanical wave, directly into the brain tissue through the skull to directly strike and stimulate mechanoreceptors within the brain tissue and induce mechanical resonance in the deep brain.

2. In Paragraph 1, The frequency selected or adjusted above is in the range of 20Hz to 80Hz, and A neural stimulation control device in which the above-mentioned controlled critical acceleration is set within the range of 0.1 m / s to 7.2 m / s within the limit of eliciting a response from a plurality of the above-mentioned mechanoreceptors.

3. In Paragraph 2, The frequency selected or adjusted above is in the range of 36Hz to 44Hz, or 72Hz to 88Hz, and A neural stimulation control device in which the above-mentioned controlled critical acceleration is precisely adjusted to a range of about 0.25 m / s to about 0.90 m / s including a variation within ±10% to 20%.

4. In any one of paragraphs 1 to 3, A neural stimulation control device that induces mechanical resonance by directly transmitting the vibrational energy accompanied by the above-mentioned controlled critical acceleration to the deep brain tissue, regardless of whether the phase of the brainwave is synchronized, by generating physical tensile force on the Piezo1 channels, which are mechanically sensitive ion channels distributed in the cell membrane, thereby inducing structural opening.

5. In Paragraph 1, The above vibration device further comprises an assembly module structure having a cone damper and a bobbin formed integrally to minimize mechanical acoustic noise generated during operation; a neural stimulation control device.

6. In Paragraph 5, A neural stimulation control device further comprising: a rubber frame that wraps around the assembly module structure and performs a spring action to prevent attenuation of the vibration energy caused by a compression phenomenon occurring when the vibration device contacts the scalp of the subject, thereby maintaining the critical acceleration to the cerebral cortex without loss.

7. In any one of paragraphs 1 to 3, A neural stimulation control device in which the mechanical resonance induced by the above-mentioned vibration device alleviates the progression of total brain volume atrophy of the subject and physically inhibits the progression of anatomical volume reduction of the hippocampus and amygdala located deep in the brain.

8. In Paragraph 1, The transcranial acoustic vibration applied by the above vibration device is, During the initial stimulation period from week 1 to week 12, the subject undergoes a first phase that temporarily increases the cohesion of the subject's overall brain network to activate neuroplasticity, and A neural stimulation control device comprising a second stage that induces functional network reorganization of a specific frequency band during the post-stimulation period, from week 13 to week 24.

9. In Paragraph 8, A neural stimulation modulator whose second stage of the above-mentioned network realignment is a process of reducing the synchronization of the subject's pathological slow wave Delta band and reorganizing the cerebral cortex network into a functional connectivity structure centered on Alpha, Beta, and Gamma bands.

10. In Paragraph 1, A neural stimulation control device that maintains brain metabolic function by inhibiting the progression of local cerebral blood flow reduction in the PCC-Precuneus region and the medial temporal region, which are brain regions including the default mode network (DMN), through the transcranial acoustic vibration applied by the above vibration device, compared to a control group applied at the threshold acceleration.

11. In Paragraph 1, A neural stimulation control device that slows the rate of deterioration of the subject's Clinical Dementia Rating Scale (CDR-SB) and Alzheimer's Disease Rating Scale (ADAS-Cog) scores by mitigating brain volume atrophy caused by the penetration of the vibration energy, which is a mechanical wave, wherein the physical transcranial acoustic vibration accompanied by the above-mentioned controlled critical acceleration is controlled to be applied continuously for at least 30 minutes per session, at least once a day.

12. In Paragraph 1, A neurostimulation control device for a subject having the above-mentioned cognitive impairment or the above-mentioned degenerative neurological disease, who is an early-stage Alzheimer's disease patient with an age of 55 years or older and 80 years or younger, a K-MMSE-2 score of 20 to 28 points, and a memory item of the CDR-SB score of 0.5 or 1 point.

13. In Paragraph 1, The above-mentioned cognitive dysfunction is a neural stimulation control device comprising one or more of attention disorder, persistent attention disorder, attention deficit hyperactivity disorder (ADHD), working memory disorder, episodic memory disorder, executive function disorder, learning disability, language disorder, psychomotor function disorder, mild cognitive impairment (MCI), and cognitive impairment accompanied by sarcopenia.

14. In Paragraph 1, The above-mentioned degenerative neurological disease is a neurostimulation control device comprising one or more of Parkinson's disease, traumatic brain injury (TBI), multiple sclerosis, drug addiction, alcohol addiction, brain inflammation, multi-organ atrophy, Huntington's disease, amyotrophic lateral sclerosis (ALS), chronic traumatic encephalopathy (CTE), motor neuronosis, dementia, Creutzfeldt-Jakob disease, and normal intracranial pressure hydrocephalus.

15. In Paragraph 14, The above dementia is a neural stimulation modulator comprising one or more of Alzheimer's disease (AD), vascular dementia, Lewy body dementia, frontotemporal dementia (FTD), AIDS-induced dementia, mixed dementia, age-related cognitive impairment, and age-related memory impairment.

16. In Paragraph 1, The vibrational energy, which is a mechanical wave accompanied by the above-mentioned controlled critical acceleration, is a neural stimulation control device that activates autophagy in neurons within the brain tissue to inhibit the hyperphosphorylation of Tau protein.

17. In Paragraph 1, A neurostimulation control device in which the above-mentioned vibrational energy, which is a mechanical wave, acts on microglia within the brain tissue to reduce the expression of neuroinflammatory mediators (IL-1β, TNF-α, IL-6) and thereby suppress neuroinflammation.

18. In Paragraph 1, The transcranial acoustic vibration generated by the above vibration device is a neural stimulation control device controlled by a sound pressure parameter of -0.80 Pa to +0.80 Pa to transmit the mechanical wave vibration energy into the brain tissue.

19. A neural stimulation modulation system for improving cognitive function in subjects with cognitive impairment or degenerative neurological disease, A vibration device worn on the head of the subject to apply physical acoustic vibrations; and A control unit for controlling the operation of the above vibration device; is included, The above control unit is a neural stimulation control system that drives the vibration device at a frequency selected or adjusted for each subject within a range of 20 Hz to 120 Hz so that transcranial acoustic vibration (tVAS) is applied to directly penetrate mechanical wave energy into the brain tissue through the skull of the subject, and at a critical acceleration that directly strikes and stimulates mechanoreceptors in the brain tissue and induces mechanical resonance in the deep brain.

20. In Paragraph 19, The above control unit is a neural stimulation control system that drives the vibration device within a frequency of 20 Hz to 80 Hz and a critical acceleration range of 0.1 m / s to 7.2 m / s to the extent that it elicits a response from a plurality of the above mechanical receptors.

21. In Paragraph 20, A neural stimulation control system in which the control unit drives the vibration device at a frequency of 36 Hz to 44 Hz or 72 Hz to 88 Hz, and precisely sets the critical acceleration to a range of about 0.25 m / s to about 0.90 m / s including a variation within a mechanical tolerance of ±10% to 20% to generate a control signal.

22. In Paragraph 19, A neural stimulation control system in which the mechanical resonance induced by the vibration device according to the control signal of the control unit alleviates the progression of atrophy of the subject's whole brain volume and induces macroscopic mechanical resonance of the subject's hippocampus and amygdala to physically defend against pathological atrophy of the limbic system structure.

23. In Paragraph 19, A neural stimulation control system configured to monitor the operation of the vibration device according to the application period and to perform a device operation protocol in 24-week units, including a neural plasticity activation period of weeks 1 to 12 of stimulation application and a brain network realignment period of weeks 13 to 24 of stimulation application.

24. In Paragraph 23, A neural stimulation control system that corrects device control parameters by confirming the effects of protecting against structural brain atrophy and realigning functional networks through brain vMRI, SPECT, and QEEG analysis of the subject after performing the above 24-week device operation protocol.

25. A method for alleviating the decline in brain function in subjects with cognitive impairment or degenerative neurological diseases, Directly striking and stimulating mechanoreceptors within the brain tissue with a frequency selected or adjusted for each subject within the range of 20Hz to 120Hz through a vibration device worn on the head of the subject, and Transcranial acoustic vibrations (tVAS) controlled by a critical acceleration that induces mechanical resonance in the deep brain are applied to penetrate directly into the brain tissue through the skull, and During the initial stimulation period of weeks 1 to 12, a first step is performed to temporarily increase the cohesion of the subject's brain network, and A method for alleviating brain function decline by performing a second step of suppressing structural atrophy of the deep brain by inducing functional network reorganization of a specific frequency band during the post-stimulation period of weeks 13 to 24.

26. In Paragraph 25, A method for mitigating brain function decline in which the applied transcranial acoustic vibration is controlled within a frequency of 20 Hz to 80 Hz and a critical acceleration range of 0.1 m / s to 7.2 m / s to the extent that it elicits a response from a plurality of the mechanoreceptors.

27. In Paragraph 26, The applied transcranial acoustic vibration is driven at a frequency of 36 Hz to 44 Hz, or 72 Hz to 88 Hz, and A method for mitigating brain function decline in which the above-mentioned critical acceleration is precisely controlled within a range of about 0.25 m / s to about 0.90 m / s, including a variation within ±10% to 20% of mechanical tolerance.

28. In Paragraph 25, The above second step is a method for alleviating brain function decline that includes a step of strengthening functional connections centered on Alpha, Beta, and Gamma bands centered on the Frontal and Central regions while reducing synchronization of the Delta band.

29. In Paragraph 25, A method for alleviating brain function decline comprising the step of performing the first and second steps above by continuously applying the vibration device at least once a day for at least 30 minutes per session to delay the reduction of local cerebral blood flow in an area including the subject's default mode network (DMN).

30. In Paragraph 25, A method for mitigating brain function decline that performs the above-mentioned first and second steps to inhibit the reduction in volume of the subject's hippocampus and amygdala, thereby producing a result of significantly delaying the rate of deterioration of the subject's Clinical Dementia Rating Scale (CDR-SB) and Alzheimer's Disease Rating Scale (ADAS-Cog) scores compared to the control group.